Wright Medical 10-Q 8 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	9 Months Ended
	Sep. 30, 2018	Nov. 02, 2018
Document Information [Line Items]
Entity Registrant Name	WRIGHT MEDICAL GROUP N.V.
Entity Central Index Key	1,492,658
Current Fiscal Year End Date	--12-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		125,081,610
Entity Current Reporting Status	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2018	Dec. 31, 2017
ThresholdForConversionAsPercentOfConversionPrice		130.00%
Current assets:
Cash and cash equivalents		$ 694,903	$ 167,740
Accounts receivable, net		122,595	130,610
Inventories		179,494	168,144
Prepaid expenses		14,935	13,555
Other current assets	[1]	311,808	86,845
Total current assets		1,323,735	566,894
Property, plant and equipment, net		221,175	212,379
Goodwill		921,376	933,662
Intangible assets, net		209,590	231,001
Deferred income taxes		905	937
Other assets	[1]	162,514	183,851
Total assets		2,839,295	2,128,724
Current liabilities:
Accounts payable		45,057	41,831
Accrued Liabilities, Current	[1]	506,322	314,558
Current portion of long-term obligations	[1],[2]	514,930	58,906
Total current liabilities		1,066,309	415,295
Long-term debt and capital lease obligations	[1]	586,582	836,208
Deferred income taxes		12,312	15,780
Other liabilities	[1]	215,594	272,745
Total liabilities		1,880,797	1,540,028
Commitments and contingencies (Note 19)
Stockholders' equity:
Common stock, $.03 par value, authorized: 320,000,000 shares; issued and outstanding: 125,065,240 shares at September 30, 2018 and 105,807,424 shares at December 31, 2017		4,573	3,896
Additional paid-in capital		2,495,851	1,971,347
Accumulated Other Comprehensive Income (Loss), Net of Tax		2,648	22,290
Retained earnings		(1,544,574)	(1,408,837)
Total stockholders' equity		958,498	588,696
Total liabilities and stockholders' equity		$ 2,839,295	$ 2,128,724
Debt Instrument, Convertible, Minimum Consecutive Period		5 days
Debt Instrument, Convertible, Trading Period		30 days
[1]	1 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. Additionally, the holders of the 2020 Notes will have the ability to begin converting their 2020 Notes beginning August 15, 2019 through their maturity. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes and the fair value of the 2020 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2020 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. See Note 6 and Note 9.
[2]	1 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes were classified as current liabilities as of September 30, 2018. The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash upon satisfaction of certain circumstances as described below. On or after August 15, 2019, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes were classified as current liabilities as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017.

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - € / shares	Sep. 30, 2018	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share	€ 0.03	€ 0.03
Common stock, shares authorized (in shares)	320,000,000	320,000,000
Common Stock, Shares, Issued	125,065,240	105,807,424

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017
Income Statement [Abstract]
Net sales		$ 194,106	$ 170,503	$ 598,043	$ 527,387
Cost of sales	[1]	44,307	38,421	131,004	113,669
Gross profit		149,799	132,082	467,039	413,718
Operating expenses:
Selling, general and administrative	[1]	139,223	131,421	417,297	392,073
Research and development	[1]	13,829	11,992	42,393	36,971
Amortization of intangible assets		5,881	7,178	19,031	21,574
Total operating expenses		158,933	150,591	478,721	450,618
Operating income		(9,134)	(18,509)	(11,682)	(36,900)
Interest Income (Expense), Nonoperating, Net		19,753	18,978	60,243	55,512
Other expense, net		3,902	5,457	75,649	6,875
Income (loss) before income taxes		(32,789)	(42,944)	(147,574)	(99,287)
Provision (benefit) for income taxes		3,040	(8,822)	(1,217)	(7,498)
Income (Loss) from Continuing Operations Attributable to Parent		(35,829)	(34,122)	(146,357)	(91,789)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent		(6,696)	(97,748)	10,620	(139,942)
Net (loss) income		$ (42,525)	$ (131,870)	$ (135,737)	$ (231,731)
Net income (loss) per share:
Net loss from continuing operations per share-basic and diluted (Note 12):		$ (0.32)	$ (0.33)	$ (1.35)	$ (0.88)
Net (loss) income from discontinued operations per share-basic and diluted (Note 12):		(0.06)	(0.93)	0.10	(1.34)
Net loss per share-basic and diluted (Note 12):		$ (0.38)	$ (1.26)	$ (1.25)	$ (2.22)
Weighted-average number of ordinary shares outstanding-basic and diluted:		113,043	104,836	108,348	104,292
[1]	1 These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017Cost of sales$141 $152 $452 $403Selling, general and administrative6,537 4,960 16,496 12,939Research and development579 333 1,388 789

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017
Cost of Sales [Member]
Stock-based compensation expense	$ 141	$ 152	$ 452	$ 403
Selling, general and administrative [Member]
Stock-based compensation expense	6,537	4,960	16,496	12,939
Research and Development [Member]
Stock-based compensation expense	$ 579	$ 333	$ 1,388	$ 789

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017
Net (loss) income	$ (42,525)	$ (131,870)	$ (135,737)	$ (231,731)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in foreign currency translation			(19,642)	44,362
Other Comprehensive Income (Loss)	(2,773)	25,132	(19,642)	44,362
Comprehensive Income (Loss)	(45,298)	(106,738)	(155,379)	(187,369)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accumulated Other Comprehensive Income (Loss) [Member]
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in foreign currency translation	$ (2,773)	$ 25,132	$ (19,642)	$ 44,362

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)		Sep. 24, 2017USD ($)
Operating activities:
Net (loss) income	$ (135,737)		$ (231,731)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	42,986		42,124
Share-based compensation expense	18,336		14,131
Amortization of intangible assets	19,031		21,574
Amortization of deferred financing costs and debt discount	40,641		37,373
Deferred income taxes	(2,976)		(2,059)
Provision for excess and obsolete inventory	17,358		13,770
Non-cash loss on extinguishment of debt	39,935		0
Non-cash adjustment to derivative fair values	34,343		(4,163)
Mark-to-market adjustment for CVRs	(3,084)		6,721
Other	617		2,093
Changes in assets and liabilities (net of acquisitions):
Accounts receivable	6,029		18,807
Inventories	(32,738)		(28,210)
Prepaid expenses and other current assets	34,847		5,851
Accounts payable	3,731		8,260
Accrued expenses and other liabilities	(23,905)		(21,343)
Metal-on-metal product liabilities (Note 13)	(71,963)		(12,506)
Net cash provided by operating activities	(12,549)		(129,308)
Investing activities:
Capital expenditures	(49,920)		(49,476)
Purchase of intangible assets	(2,288)		(1,408)
Investments	(500)
Net cash used in investing activities	(52,708)		(50,884)
Financing activities:
Issuance of ordinary shares	10,975		24,828
Proceeds from equity offering	448,924
Payment of equity offering costs	(25,566)
Issuance of warrants	102,137		0
Payment of notes premium	(55,643)		0
Payment of notes hedge options	141,278		0
Repurchase of stock warrants	(23,972)
Payment of equity issuance costs	(1,870)
Proceeds from notes hedge options	34,553
Proceeds from exchangeable senior notes	675,000		0
Proceeds from other debt	23,434		32,000
Payments of debt	(34,067)		(10,722)
Redemption of convertible senior notes	400,911		0
Payments of deferred financing costs	(14,092)		0
Payment of contingent consideration	(919)		(1,429)
Payments of capital lease obligations	(3,905)		(1,863)
Net cash provided by financing activities	592,800		42,814
Effect of exchange rates on cash and cash equivalents	(380)		2,902
Net increase (decrease) in cash and cash equivalents	527,163		(134,476)
Consolidated cash and cash equivalents, beginning of year	167,740	[1]	412,265	[1]
Consolidated Cash and Equivalents, end of year	$ 694,903	[1]	277,789	[1]
Cash			238,900
Restricted Cash			$ 38,900
[1]	1 As of September 24, 2017 and December 25, 2016, we had cash and cash equivalents of $238.9 million and $262.3 million, respectively. As of September 24, 2017 and December 25, 2016, we had $38.9 million and $150.0 million, respectively, in restricted cash to secure our obligations under a Master Settlement Agreement (MSA) that WMT entered into in connection with the metal-on-metal hip litigation as described in Note 13.

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2018
Organization and Description of Business [Abstract]
Organization and Description of Business	Organization and Description of Business Wright Medical Group N.V. (Wright or we) is a global medical device company focused on extremities and biologics products. We are committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and are a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. We market our products in approximately 50 countries worldwide. Our global corporate headquarters are located in Amsterdam, the Netherlands. We also have significant operations located in Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative activities); Bloomington, Minnesota (upper extremities sales and marketing and warehousing operations); Arlington, Tennessee (manufacturing and warehousing operations); Franklin, Tennessee (manufacturing and warehousing operations); Warsaw, Indiana (research and development); Alpharetta, Georgia (manufacturing and warehousing operations); Montbonnot, France (manufacturing and warehousing operations); Plouzané, France (research and development); and Macroom, Ireland (manufacturing). In addition, we have local sales and distribution offices in Canada, Australia, Asia, Latin America, and throughout Europe. For purposes of this report, references to "international" or "foreign" relate to non-U.S. matters while references to "domestic" relate to U.S. matters. Our fiscal year-end is generally determined on a 52-week basis and runs from the Monday nearest to the 31st of December of a year and ends on the Sunday nearest to the 31st of December of the following year. Every few years, it is necessary to add an extra week to the year making it a 53-week period. The fiscal year ended December 31, 2017 was a 53-week period. The condensed consolidated financial statements and accompanying notes present our consolidated results for each of the three and nine months ended September 30, 2018 and September 24, 2017 . The three and nine months ended September 30, 2018 and September 24, 2017 each consisted of thirteen and thirty-nine weeks, respectively. All amounts are presented in U.S. dollars ($), except where expressly stated as being in other currencies, e.g., Euros (€). References in these notes to the condensed consolidated financial statements to "we," "our" and "us" refer to Wright Medical Group N.V. and its subsidiaries after the merger with Tornier N.V. (legacy Tornier) (Wright/Tornier merger) and Wright Medical Group, Inc. (WMG or legacy Wright) and its subsidiaries before the Wright/Tornier merger.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation. The unaudited condensed consolidated interim financial statements of Wright Medical Group N.V. have been prepared in accordance with U.S. generally accepted accounting principles (US GAAP) for interim financial statements and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to these rules and regulations. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 , as filed with the SEC on February 27, 2018 . In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary for a fair presentation of our interim financial results. All such adjustments are of a normal and recurring nature. The results of operations for any interim period are not indicative of results for the full fiscal year. The accompanying unaudited condensed consolidated interim financial statements include our accounts and those of our controlled subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the dates of the financial statements and the amounts of revenues and expenses during the reporting periods. Actual amounts realized or paid could differ from those estimates. Revenue recognition. Our revenues are primarily generated through two types of customers, hospitals and surgery centers and stocking distributors, with the majority of our revenue derived from sales to hospitals and surgery centers. Our products are sold through a network of employee and independent sales representatives in the United States and by a combination of employee sales representatives, independent sales representatives, and stocking distributors outside the United States. We record revenues from sales to hospitals and surgery centers upon transfer of control of promised products in an amount that reflects the consideration we expect to receive in exchange for those products, which is generally when the product is surgically implanted in a patient. We record revenues from sales to our stocking distributors at a point in time upon transfer of control of promised products to the distributor. Our stocking distributors, who sell the products to their customers, take control of the products and assume all risks of ownership upon transfer. Our stocking distributors are obligated to pay us within specified terms regardless of when, if ever, they sell the products. In general, our stocking distributors do not have any rights of return or exchange; however, in limited situations, we have repurchase agreements with certain stocking distributors. Those certain agreements require us to repurchase a specified percentage of the inventory purchased by the distributor within a specified period of time prior to the expiration of the contract. During those specified periods, we defer the applicable percentage of the sales. An insignificant amount of sales related to these types of agreements was deferred and not yet recognized as revenue as of September 30, 2018 and December 31, 2017. We must make estimates of potential future product returns related to current period product sales. We base our estimate for sales returns on historical sales and product return information, including historical experience and trend information. Our reserve for sales returns has historically been immaterial. We incur shipping and handling costs associated with the shipment of goods to customers, independent distributors, and our subsidiaries. Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products to customers are included in selling, general and administrative expenses. We also record depreciation on surgical instruments used by our hospital and surgery center customers within selling, general and administrative expense as these costs are considered to be similar to shipping and handling costs, necessary to deliver the implant products to the end customer. Discontinued Operations. On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France SAS (Tornier France) and certain other entities related to us and Corin Orthopaedics Holdings Limited (Corin) entered into a business sale agreement and simultaneously completed and closed the sale of our former Large Joints business. Pursuant to the terms of the agreement, we sold substantially all of our assets related to our Large Joints business to Corin for approximately €29.7 million in cash, less approximately €11.1 million for net working capital adjustments. Upon closing, the parties also executed a transitional services agreement and supply agreement, among other ancillary agreements required to implement the transaction. These agreements were on arm’s length terms and were not material to our consolidated financial statements. On January 9, 2014, pursuant to an Asset Purchase Agreement, dated as of June 18, 2013 (the MicroPort Agreement), by and among us and MicroPort Scientific Corporation (MicroPort), we completed the divesture and sale of our business operations operating under our prior OrthoRecon operating segment to MicroPort. All historical operating results for the Large Joints and OrthoRecon businesses are reflected within discontinued operations in the condensed consolidated financial statements. See Note 4 for further discussion of discontinued operations. Other than Note 4 , unless otherwise stated, all discussion of assets and liabilities in these Notes to the condensed consolidated financial statements reflects the assets and liabilities held and used in our continuing operations, and all discussion of revenues and expenses reflects those associated with our continuing operations. Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, and has subsequently issued several supplemental and/or clarifying ASUs (collectively ASC 606). Accounting Standards Codification (ASC) 606 prescribes a single common revenue standard that replaces most existing US GAAP revenue recognition guidance. ASC 606 outlines a five-step model, under which we will recognize revenue as performance obligations within a customer contract are satisfied. ASC 606 is intended to provide more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. We adopted ASC 606 during the quarter ended April 1, 2018. Revenue is recognized at a point in time, generally upon surgical implantation or shipment of products to distributors. Therefore, adoption of ASC 606 did not have a material effect on our consolidated financial statements except for the additional disclosures included within Note 14 . On February 25, 2016, the FASB issued ASU 2016-02, Leases, and has subsequently issued ASU 2018-10 and ASU 2018-11 which clarifies this guidance (collectively ASC 842). ASC 842 introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in FASB ASC 606, the FASB’s new revenue recognition standard (e.g., those related to evaluating when profit can be recognized). Furthermore, ASC 842 addresses other concerns related to the current leases model. ASC 842 will be effective for us beginning in fiscal year 2019. We have evaluated the practical expedients and plan to adopt the hindsight practical expedient, the practical expedient for short-term leases, the practical expedient package which primarily limits the need for reassessing lease classification on existing leases, and to issue our financial statements showing comparative lease disclosures under current GAAP. We do not anticipate adoption of these updates will have a material impact on net earnings or cash flows and continue to assess the impact on our consolidated balance sheets. On January 26, 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of step 2 of the goodwill impairment test. Under the new guidance, if a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The guidance in the ASU is effective for our interim and annual goodwill impairment tests beginning in 2020 with early adoption permitted. We are in the initial phases of our adoption plans; and, accordingly, we are unable to estimate any effect this may have on our consolidated financial statements.

Acquisitions (Notes)

Acquisitions (Notes)	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Acquisitions	Acquisitions IMASCAP On December 14, 2017, we completed the acquisition of IMASCAP SAS (IMASCAP), a leader in the development of software-based solutions for preoperative planning of shoulder replacement surgery. The intent of this transaction is to ensure exclusive access to breakthrough software enabling technology and patents to further differentiate our product portfolio and to further accelerate growth opportunities in our global extremities business. Under the terms of the agreement with IMASCAP, we acquired 100% of IMASCAP’s outstanding equity on a fully diluted basis for an initial payment of €52.9 million , or approximately $62.3 million , consisting of approximately €39.7 million , or approximately $46.7 million , in cash and approximately €13.2 million , or approximately $15.6 million , representing 661,753 Wright ordinary shares, payable at closing. Additionally, the purchase price included an estimated €15.1 million , or approximately $17.8 million , of contingent consideration related to the achievement of certain technical milestones and sales earnouts. The technical milestones involve the development and approval of a next generation reverse shoulder implant system and new software modules. The sales earnouts relate to certain guides and the next generation reverse shoulder implant system. Purchase Consideration and Net Assets Acquired The following presents the preliminary allocation of the purchase consideration to the assets acquired and liabilities assumed on December 14, 2017 (in thousands): Cash and cash equivalents $ 2,559 Accounts receivable 102 Other current assets 925 Property, plant and equipment 20 Intangible assets 10,865 Total assets acquired 14,471 Current liabilities (2,173 ) Long-term debt (886 ) Deferred income taxes (2,343 ) Total liabilities assumed (5,402 ) Net assets acquired $ 9,069 Goodwill 71,064 Total preliminary purchase consideration $ 80,133 The purchase consideration was allocated to the net assets acquired based on their estimated fair values at the acquisition date. The fair values were based on management’s analysis, including work performed by third-party valuation specialists. Operating assets and liabilities were valued at their existing carrying values as they represented the fair value of those items at the acquisition date, based on management’s judgments and estimates. In determining the fair value of intangibles, we used an income method which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates and profitability), technology life cycles, and the discount rate applied to the cash flows. Of the $10.9 million of acquired intangible assets, $5.6 million was assigned to developed technology ( 6 -year life) and $5.3 million was assigned to in-process research and development. The excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of IMASCAP. The goodwill is not expected to be deductible for tax purposes. During the nine months ended September 30, 2018 , we revised opening balances acquired as a result of the IMASCAP acquisition, primarily for accounts receivable; other current assets; accrued expenses and other current liabilities; and deferred tax liabilities which resulted in a $0.9 million decrease in the preliminary value of goodwill determined as of December 14, 2017.

Discontinued Operations (Notes)

Discontinued Operations (Notes)	9 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Discontinued Operations For the three months ended September 30, 2018 , our loss from discontinued operations, net of tax, totaled $6.7 million . For the nine months ended September 30, 2018, our income from discontinued operations, net of tax, totaled $10.6 million . For the three and nine months ended September 24, 2017 , our loss from discontinued operations, net of tax, totaled $97.7 million and $139.9 million , respectively. Our operating results from discontinued operations during 2018 and 2017 were attributable primarily to expenses, net of insurance recoveries, associated with legacy Wright's former OrthoRecon business as described in Note 13 and, to a lesser degree, the former Large Joints business. Large Joints Business On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France, Corin, and certain other entities related to us and Corin entered into a business sale agreement and simultaneously completed and closed the sale of our Large Joints business. Pursuant to the terms of the agreement, we sold substantially all of the assets related to our Large Joints business to Corin for approximately €29.7 million in cash, less approximately € 11.1 million for net working capital adjustments. Upon closing, the parties also executed a transitional services agreement and supply agreement, among other ancillary agreements required to implement the transaction. These agreements are on arm’s length terms and are not expected to be material to our condensed consolidated financial statements. All historical operating results for the Large Joints business as well as continued involvement in accordance with the transitional service agreement and supply agreement are reflected within discontinued operations in the condensed consolidated statements of operations. For the three and nine months ended September 30, 2018 , our loss from discontinued operations for the Large Joints business, net of tax, totaled $0.3 million and $0.7 million , respectively, and are primarily attributable to costs associated with transition services. For the three and nine months ended September 24, 2017 , our loss from discontinued operations for the Large Joints business, net of tax, totaled $0.9 million and $2.4 million , respectively, and are primarily attributable to professional fees and internal costs to support transition activities, costs associated with transition services and working capital adjustments. Cash provided by operating activities from the Large Joints business totaled $2.7 million for the nine months ended September 30, 2018 . Cash used in operating activities by the Large Joints business totaled $3.5 million for the nine months ended September 24, 2017 . OrthoRecon Business On January 9, 2014, legacy Wright completed the divestiture and sale of its OrthoRecon business to MicroPort Scientific Corporation. Certain liabilities associated with the OrthoRecon business, including product liability claims associated with hip and knee products sold by legacy Wright prior to the closing, were not assumed by MicroPort. Charges associated with these product liability claims, including legal defense, settlements and judgments, income associated with product liability insurance recoveries, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected within results of discontinued operations, and we will continue to reflect these within results of discontinued operations in future periods. As described within Note 13 , in September 2015, the third insurance carrier in the policy year applicable to titanium modular neck fracture claims denied coverage under its $25 million excess liability policy despite full payout by the other carriers in that policy year. We strongly disputed the carrier's position and, in accordance with the dispute resolution provisions of the policy, initiated an arbitration proceeding in London, England seeking payment of these funds. The arbitration proceeding was completed on February 15, 2018 and, on April 11, 2018, the arbitration tribunal issued its ruling. Thereafter, we and the insurance carrier agreed to resolve the entire matter in exchange for a single lump sum payment by the carrier to us in the amount of $30.75 million , representing the full policy limits of $25 million plus an additional $5.75 million for legal costs and interest. We received payment of this sum from the carrier on May 8, 2018. This insurance recovery is reflected within our results of discontinued operations for the quarter ended July 1, 2018. All current and historical operating results for the OrthoRecon business are reflected within discontinued operations in the condensed consolidated financial statements. The following table summarizes the results of discontinued operations for the OrthoRecon business (in thousands): Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 Net sales $ — $ — $ — $ — Selling, general and administrative 8,553 96,917 (15,309 ) 137,578 (Loss) income from discontinued operations before income taxes (8,553 ) (96,917 ) 15,309 (137,578 ) (Benefit) provision for income taxes (2,188 ) — 3,995 — Total (loss) income from discontinued operations, net of tax $ (6,365 ) $ (96,917 ) $ 11,314 $ (137,578 ) We will incur continuing cash outflows associated with legal defense costs and the ultimate resolution of these contingent liabilities, net of insurance proceeds, until these liabilities are resolved. Cash used in operating activities by the OrthoRecon business totaled $46.8 million and $142.7 million for the nine months ended September 30, 2018 and September 24, 2017 , respectively.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials $ 10,517 $ 10,816 Work-in-process 36,029 28,581 Finished goods 132,948 128,747 $ 179,494 $ 168,144

Derivatives and Fair Value of F

Derivatives and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Derivatives and Fair Value [Text Block]	Fair Value of Financial Instruments and Derivatives We account for derivatives in accordance with FASB ASC 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivatives' fair value shall be recognized currently in earnings unless specific hedge accounting criteria are met. FASB ASC Section 820, Fair Value Measurement requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Financial instruments with unadjusted, quoted prices listed on active market exchanges. Level 2: Financial instruments determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques. 2023 Notes Conversion Derivative and Notes Hedges On June 28, 2018, we issued $675 million aggregate principal amount of 1.625% cash exchangeable senior notes due 2023 (2023 Notes). The 2023 Notes are referred to as "exchangeable" in the 2023 Notes Indenture (as defined in Note 9 ) because they were issued by WMG, not us. See Note 9 of the condensed consolidated financial statements for additional information regarding the 2023 Notes. The 2023 Notes have a conversion derivative feature (2023 Notes Conversion Derivative) that requires bifurcation from the 2023 Notes in accordance with ASC Topic 815 and is accounted for as a derivative liability. The fair value of the 2023 Notes Conversion Derivative at the time of issuance of the 2023 Notes was $124.6 million . In connection with the issuance of the 2023 Notes, we entered into hedges (2023 Notes Hedges) with two option counterparties. The 2023 Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2023 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The aggregate cost of the 2023 Notes Hedges was $141.3 million and is accounted for as a derivative asset in accordance with ASC Topic 815. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2023 Note Hedges, which may reduce the effectiveness of the 2023 Note Hedges. The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2023 Notes Hedges and 2023 Notes Conversion Derivative: Location on condensed consolidated balance sheet September 30, 2018 2023 Notes Hedges Other assets $ 150,853 2023 Notes Conversion Derivative Other liabilities $ 151,107 The 2023 Notes Hedges and the 2023 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs. Neither the 2023 Notes Conversion Derivative nor the 2023 Notes Hedges qualify for hedge accounting; thus, any changes in the fair value of the derivatives are recognized immediately in our condensed consolidated statements of operations. The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2023 Notes Hedges and 2023 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 30, 2018 2023 Notes Hedges $ 25,880 $ 9,575 2023 Notes Conversion Derivative (25,244 ) (26,482 ) Net gain (loss) on changes in fair value $ 636 $ (16,907 ) 2021 Notes Conversion Derivative and Notes Hedges On May 20, 2016 , we issued $395 million aggregate principal amount of 2.25% cash convertible senior notes due 2021 (2021 Notes). See Note 9 of the condensed consolidated financial statements for additional information regarding the 2021 Notes. The 2021 Notes have a conversion derivative feature (2021 Notes Conversion Derivative) that requires bifurcation from the 2021 Notes in accordance with ASC Topic 815 and is accounted for as a derivative liability. The fair value of the 2021 Notes Conversion Derivative at the time of issuance of the 2021 Notes was $117.2 million . In connection with the issuance of the 2021 Notes, we entered into hedges (2021 Notes Hedges) with two option counterparties. The 2021 Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that we are required to make upon conversion of the 2021 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The aggregate cost of the 2021 Notes Hedges was $99.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2021 Note Hedges, which may reduce the effectiveness of the 2021 Note Hedges. The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2021 Notes Hedges and 2021 Notes Conversion Derivative: September 30, 2018 December 31, 2017 Location on condensed consolidated balance sheet Amount Location on condensed consolidated balance sheet Amount 2021 Notes Hedges Other current assets $ 222,919 Other assets $ 127,063 2021 Notes Conversion Derivative Accrued expenses and other current liabilities $ 221,356 Other liabilities $ 126,148 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. We currently do not expect significant conversions because the 2021 Notes currently trade at a premium to the as-converted value, and a converting holder would forego future interest payments. However, any conversions would reduce our cash resources. We believe that, in the event that holders elect to exercise the conversion option, our cash resources and access to additional borrowings would provide the necessary liquidity. The 2021 Notes Hedges and the 2021 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs. Neither the 2021 Notes Conversion Derivative nor the 2021 Notes Hedges qualify for hedge accounting; thus, any changes in the fair value of the derivatives are recognized immediately in our condensed consolidated statements of operations. The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2021 Notes Hedges and 2021 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 2021 Notes Hedges $ 46,591 $ (9,074 ) $ 95,856 $ 18,723 2021 Notes Conversion Derivative (45,715 ) 9,321 (95,208 ) (16,269 ) Net gain on changes in fair value $ 876 $ 247 $ 648 $ 2,454 2020 Notes Conversion Derivative and Notes Hedges On February 13, 2015 , WMG issued $632.5 million aggregate principal amount of 2.00% cash convertible senior notes due 2020 (2020 Notes). See Note 9 of the condensed consolidated financial statements for additional information regarding the 2020 Notes. The 2020 Notes have a conversion derivative feature (2020 Notes Conversion Derivative) that requires bifurcation from the 2020 Notes in accordance with ASC Topic 815 and is accounted for as a derivative liability. The fair value of the 2020 Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million . In connection with the issuance of the 2020 Notes, WMG entered into hedges (2020 Notes Hedges) with three option counterparties. The 2020 Notes Hedges, which are cash-settled, are generally intended to reduce WMG's exposure to potential cash payments that WMG is required to make upon conversion of the 2020 Notes in excess of the principal amount of converted notes if our ordinary share price exceeds the conversion price. The aggregate cost of the 2020 Notes Hedges was $144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2020 Note Hedges, which may reduce the effectiveness of the 2020 Note Hedges. Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2020 Notes exchanged approximately $45 million aggregate principal amount of 2020 Notes for the 2021 Notes. For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $990.00 principal amount of the 2021 Notes (subject, in each case, to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2020 Notes and the rounded amount at an aggregate cost of approximately $44.6 million . We settled the associated portion of the 2020 Notes Conversion Derivative at a benefit of approximately $0.4 million and satisfied the accrued interest, which was not material. In addition, during the second quarter of 2016, we settled a portion of the 2020 Notes Hedges (receiving $3.9 million ) and repurchased a portion of the warrants associated with the 2020 Notes (paying $3.3 million ), generating net proceeds of approximately $0.6 million . Concurrently with the issuance and sale of the 2023 Notes, certain holders of the 2020 Notes exchanged approximately $400.9 million aggregate principal amount of their 2020 Notes for the 2023 Notes. For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $1,138.70 principal amount of the 2023 Notes (subject to rounding down to the nearest $1,000 principal amount of the 2023 Notes for each exchanging investor, the difference being referred as the rounded amount) to the investor. As part of this exchange we settled a pro rata portion of the 2020 Notes Conversion Derivative for $55.6 million . During the second quarter of 2018, we agreed to settle a pro rata portion of the 2020 Notes Hedges. We also agreed to repurchase a pro rata portion of the warrants associated with the 2020 Notes (2020 Warrants Derivative) and recorded a derivative liability which had a fair value of $27.3 million as of June 28, 2018. Prior to this agreement, the warrants were recorded within shareholders' equity as, at that time, the warrants were expected to be net-share settled. The pricing of the settled portion of the 2020 Notes Hedges and 2020 Warrants Derivative was based on the volume-weighted average price of our stock price during July 9, 2018 and July 27, 2018, the unwind period. On July 30, 2018, we received proceeds of approximately $34.6 million related to the 2020 Notes Hedges and paid $24.0 million related to the 2020 Warrants Derivative, generating net proceeds of $10.6 million . As of September 30, 2018, we had warrants on the 2020 Notes which were exercisable for 6.2 million ordinary shares with a strike price of $38.8010 per ordinary share. The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2020 Notes Hedges and 2020 Notes Conversion Derivative: September 30, 2018 December 31, 2017 Location on condensed consolidated balance sheet Amount Location on condensed consolidated balance sheet Amount 2020 Notes Hedges Other current assets $ 27,327 Other assets $ 45,033 2020 Notes Conversion Derivative Accrued expenses and other current liabilities $ 26,757 Other liabilities $ 44,132 The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash upon satisfaction of certain circumstances as described in Note 9 . On or after August 15, 2019, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes and the fair value of the 2020 Notes Conversion Derivatives were classified as current liabilities and the fair value of the 2020 Notes Hedges was classified as current assets as of September 30, 2018. The respective balances were all classified as long-term as of December 31, 2017. The 2020 Notes Hedges, 2020 Notes Conversion Derivative, and the 2020 Warrants Derivative are measured at fair value using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs. Neither the 2020 Notes Conversion Derivative, 2020 Notes Hedges nor the 2020 Warrants Derivative qualify for hedge accounting; thus, any change in the fair value of the derivatives is recognized immediately in our condensed consolidated statements of operations. Changes in the fair value of the 2020 Warrants Derivative and the portion of the 2020 Notes Hedges which were settled between June 28, 2018 and the cash settlement date are included within our condensed consolidated statements of operations. The following table summarizes the net (loss) gain on changes in fair value (in thousands) related to the 2020 Notes Hedges, 2020 Warrants Derivative and 2020 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 2020 Notes Hedges $ 3,317 $ (10,340 ) $ 16,847 $ (3,538 ) 2020 Warrants Derivative 3,586 — 3,336 — 2020 Notes Conversion Derivative (8,186 ) 10,292 (38,268 ) 5,298 Net (loss) gain on changes in fair value $ (1,283 ) $ (48 ) $ (18,085 ) $ 1,760 2017 Notes Conversion Derivative and Notes Hedges On August 31, 2012 , WMG issued $300 million aggregate principal amount of 2.00% cash convertible senior notes due 2017 (2017 Notes). The 2017 Notes matured, and the remaining $2 million principal amount was repaid on August 15, 2017. See Note 9 of the condensed consolidated financial statements for additional information regarding the 2017 Notes. The 2017 Notes had a conversion derivative feature (2017 Notes Conversion Derivative) that required bifurcation from the 2017 Notes in accordance with ASC Topic 815 and was accounted for as a derivative liability. The fair value of the 2017 Notes Conversion Derivative at the time of issuance of the 2017 Notes was $48.1 million . In connection with the issuance of the 2017 Notes, WMG entered into hedges (2017 Notes Hedges) with three option counterparties. The aggregate cost of the 2017 Notes Hedges was $56.2 million and was accounted for as a derivative asset in accordance with ASC Topic 815. In connection with the issuance of the 2020 Notes, WMG used approximately $292 million of the 2020 Notes' net proceeds to repurchase and extinguish approximately $240 million aggregate principal amount of the 2017 Notes, settle the associated portion of the 2017 Notes Conversion Derivative at a cost of approximately $49 million , and satisfy the accrued interest of $2.4 million . WMG also settled all of the 2017 Notes Hedges (receiving $70 million ) and repurchased all of the warrants associated with the 2017 Notes (paying $60 million ), generating net proceeds of approximately $10 million . Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes exchanged approximately $54.4 million aggregate principal amount of 2017 Notes (including the 2017 Notes Conversion Derivative) for the 2021 Notes. For each $1,000 principal amount of 2017 Notes validly submitted for exchange, we delivered $1,035.40 principal amount of the 2021 Notes (subject, in each case, to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2017 Notes and the rounded amount at a cost of approximately $56.3 million . We settled the associated portion of the 2017 Notes Conversion Derivative at a cost of approximately $1.9 million and satisfied the accrued interest, which was not material. In addition, during the second quarter of 2016, we repurchased and extinguished an additional $3.6 million aggregate principal amount of the 2017 Notes in privately negotiated transactions and settled the associated portion of the 2017 Notes Conversion Derivative at a cost of approximately $0.1 million , and satisfied the accrued interest, which was not material. The remainder of the 2017 Notes Conversion Derivative was settled at a cost of approximately $0.2 million in conjunction with the maturity of the 2017 Notes on August 15, 2017. The 2017 Notes Conversion Derivative was measured at fair value using Level 3 inputs. This instrument was not actively traded and was valued using an option pricing model that used observable and unobservable market data for inputs. Neither the 2017 Notes Conversion Derivative nor the 2017 Notes Hedges qualified for hedge accounting; thus, any change in the fair value of the derivatives was recognized immediately in our condensed consolidated statements of operations. The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2017 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 2017 Notes Conversion Derivative $ — $ 15 $ — $ (51 ) Net gain (loss) on changes in fair value $ — $ 15 $ — $ (51 ) To determine the fair value of the embedded conversion option in the 2020, 2021, and 2023 Notes Conversion Derivatives, a trinomial lattice model was used. A trinomial stock price lattice generates three possible outcomes of stock price - one up, one down, and one stable. This lattice generates a distribution of stock prices at the maturity date and throughout the life of the 2020, 2021, and 2023 Notes. Using this stock price lattice, a convertible note lattice was created where the value of the embedded conversion option was estimated by comparing the value produced in a convertible note lattice with the option to convert against the value without the ability to convert. In each case, the convertible note lattice first calculates the possible convertible note values at the maturity date, using the distribution of stock prices, which equals to the maximum of (x) the remaining bond cash flows and (y) stock price times the conversion price. The values of the 2020, 2021, and 2023 Notes Conversion Derivatives at the valuation date were estimated using the values at the maturity date and moving back in time on the lattices (both for the lattice with the conversion option and without the conversion option). Specifically, at each node, if the 2020, 2021, or 2023 Notes are eligible for early conversion, the value at this node is the maximum of (i) converting to stock, which is the stock price times the conversion price, and (ii) holding onto the 2020, 2021, and 2023 Notes, which is the discounted and probability-weighted value from the three possible outcomes at the future nodes plus any accrued but unpaid coupons that are not considered at the future nodes. If the 2020, 2021, or 2023 Notes are not eligible for early conversion, the value of the conversion option at this node equals to (ii). In the lattice, a credit adjustment was applied to the discount for each cash flow in the model as the embedded conversion option, as well as the coupon and notional payments, is settled with cash instead of shares. To estimate the fair value of the 2020, 2021 and 2023 Notes Hedges, we used the Black-Scholes formula combined with credit adjustments, as the option counterparties have credit risk and the call options are cash settled. We assumed that the call options will be exercised at the maturity since our ordinary shares do not pay any dividends and management does not expect to declare dividends in the near term. The following assumptions were used in the fair market valuations as of September 30, 2018 : 2020 Notes Conversion Derivative 2020 Notes 2021 Notes Conversion Derivative 2021 Notes Hedge 2023 Notes Conversion Derivative 2023 Notes Hedge Stock Price Volatility (1) 31.92% 31.92% 37.55% 37.55% 30.64% 30.64% Credit Spread for Wright (2) 2.62% N/A 3.13% N/A 2.55% N/A Credit Spread for Deutsche Bank AG (3) N/A 1.27% N/A N/A N/A N/A Credit Spread for Wells Fargo Securities, LLC (3) N/A 0.15% N/A N/A N/A N/A Credit Spread for JPMorgan Chase Bank (3) N/A 0.17% N/A 0.27% N/A 0.4% Credit Spread for Bank of America (3) N/A N/A N/A 0.28% N/A 0.46% (1) Volatility selected based on historical and implied volatility of ordinary shares of Wright Medical Group N.V. (2) Credit spread implied from traded price. (3) Credit spread of each bank is estimated using CDS curves. Source: Bloomberg. Derivatives not Designated as Hedging Instruments During 2017, we employed a derivative program using foreign currency forward contracts to mitigate the risk of currency fluctuations on our intercompany receivable and payable balances that are denominated in foreign currencies. These forward contracts were expected to offset the transactional gains and losses on the related intercompany balances. These forward contracts were not designated as hedging instruments under FASB ASC Topic 815. Accordingly, the changes in the fair value and the settlement of the contracts were recognized in the period incurred in the accompanying condensed consolidated statements of operations. During the quarter ended April 1, 2018, we discontinued our foreign currency forward contracts derivative program. At September 30, 2018 and December 31, 2017 , we had no foreign currency contracts outstanding. As a result of the acquired sales and distribution business of Surgical Specialties Australia Pty. Ltd in 2015, we had recorded the estimated fair value of future contingent consideration of approximately $0.9 million as of December 31, 2017 which was paid during the quarter ended April 1, 2018. As a result of the acquired business of IMASCAP in 2017, we have recorded the estimated fair value of future contingent consideration of approximately €16.1 million , or approximately $18.6 million , related to the achievement of certain technical milestones and sales earnouts as of September 30, 2018. The estimated fair value of contingent consideration related to technical milestones totaled $12.4 million and $11.9 million as of September 30, 2018 and December 31, 2017, respectively, and is contingent upon the development and approval of a next generation reverse shoulder implant system and new software modules. The estimated fair value of contingent consideration related to sales earnouts totaled $6.3 million and $5.9 million as of September 30, 2018 and December 31, 2017, respectively, and is contingent upon the sale of certain guides and the next generation reverse shoulder implant system. The fair values of the sales earn out contingent consideration as of September 30, 2018 and December 31, 2017 were determined using a discounted cash flow model and probability adjusted estimates of the future earnings and is classified in Level 3. The discount rate is 12% for IMASCAP and was 14% for Surgical Specialties Australia Pty. Ltd. The contingent consideration from the IMASCAP acquisition related to technical milestones is based on meeting certain developmental milestones for new software modules and for the FDA and CE approval for the next generation reverse shoulder implant system. The fair value of this contingent consideration as of September 30, 2018 and December 31, 2017 was determined using probability adjusted estimates of the future payments and is classified in Level 3. The discount rate is approximately 6% for IMASCAP. A change in the discount rate would have limited impact on our profits or the fair value of this contingent consideration. On March 1, 2013, as part of our acquisition of BioMimetic Therapeutics, Inc. (BioMimetic), we issued Contingent Value Rights (CVRs) as part of the merger consideration. Each CVR entitles its holder to receive additional cash payments of up to $6.50 per share, which are payable upon receipt of FDA approval of AUGMENT ® Bone Graft and upon achieving certain revenue milestones. On September 1, 2015, AUGMENT ® Bone Graft received FDA approval and the first of the milestone payments associated with the CVRs was paid out at $3.50 per share, which totaled $98.1 million . The fair value of the CVRs outstanding at September 30, 2018 and December 31, 2017 was $39.2 million and $42.3 million , respectively, and was determined using the closing price of the security in the active market (Level 1), and is reflected within "Accrued expenses and other current liabilities" on our condensed consolidated balance sheet. For the three months ended September 30, 2018 and September 24, 2017 , the change in the fair value of the CVRs resulted in expense of $3.4 million and $4.5 million , respectively. For the nine months ended September 30, 2018 and September 24, 2017 , the change in the fair value of the CVRs resulted in income of $3.1 million and expense of $6.7 million , respectively. The income or expense related to the change in the value of the CVRs is recorded in “Other expense, net” in our condensed consolidated statements of operations. If, prior to March 1, 2019, sales of AUGMENT ® Bone Graft reach $40 million over 12 consecutive months, cash payment would be required at $1.50 per share, or $42 million . Sales for AUGMENT ® Bone Graft reached $40 million for the 12 months ended October 28, 2018 which will result in the $42 million payment during the fourth quarter of 2018. Further, if, prior to March 1, 2019, sales of AUGMENT ® Bone Graft reach $70 million over 12 consecutive months, an additional cash payment would be required at $1.50 per share, or $42 million . The carrying value of cash and cash equivalents, accounts receivable, and accounts payable approximates the fair value of these financial instruments at September 30, 2018 and December 31, 2017 due to their short maturities and variable rates. The following tables summarize the valuation of our financial instruments (in thousands): Total Quoted prices in active markets (Level 1) Prices with other observable inputs (Level 2) Prices with unobservable inputs (Level 3) At September 30, 2018 Assets Cash and cash equivalents $ 694,903 $ 694,903 $ — $ — 2020 Notes Hedges 27,327 — — 27,327 2021 Notes Hedges 222,919 — — 222,919 2023 Notes Hedges 150,853 — — 150,853 Total $ 1,096,002 $ 694,903 $ — $ 401,099 Liabilities 2020 Notes Conversion Derivative $ 26,757 $ — $ — $ 26,757 2021 Notes Conversion Derivative 221,356 — — 221,356 2023 Notes Conversion Derivative 151,107 — — 151,107 Contingent consideration 18,765 — — 18,765 Contingent consideration (CVRs) 39,241 39,241 — — Total $ 457,226 $ 39,241 $ — $ 417,985 Total Quoted prices Prices with Prices with At December 31, 2017 Assets Cash and cash equivalents $ 167,740 $ 167,740 $ — $ — 2020 Notes Hedges 45,033 — — 45,033 2021 Notes Hedges 127,063 — — 127,063 Total $ 339,836 $ 167,740 $ — $ 172,096 Liabilities 2020 Notes Conversion Derivative $ 44,132 $ — $ — $ 44,132 2021 Notes Conversion Derivative 126,148 — — 126,148 Contingent consideration 19,188 — — 19,188 Contingent consideration (CVRs) 42,325 42,325 — — Total $ 231,793 $ 42,325 $ — $ 189,468 The following is a roll forward of our assets and liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) (in thousands): Balance at December 31, 2017 Additions Transfers into Level 3 Gain/(loss) included in earnings Settlements Currency Balance at September 30, 2018 2020 Notes Hedges $ 45,033 — — 16,847 (34,553 ) — $ 27,327 2020 Notes Conversion Derivative $ (44,132 ) — — (38,268 ) 55,643 — $ (26,757 ) 2020 Warrants Derivative $ — (27,308 ) — 3,336 23,972 — $ — 2021 Notes Hedges $ 127,063 — — 95,856 — — $ 222,919 2021 Notes Conversion Derivative $ (126,148 ) — — (95,208 ) — — $ (221,356 ) 2023 Notes Hedges $ — 141,278 — 9,575 — — $ 150,853 2023 Notes Conversion Derivative $ — (124,625 ) — (26,482 ) — — $ (151,107 ) Contingent consideration $ (19,188 ) — — (1,280 ) 919 784 $ (18,765 )

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment, net consists of the following (in thousands): September 30, 2018 December 31, 2017 Property, plant and equipment, at cost $ 519,226 $ 448,921 Less: Accumulated depreciation (298,051 ) (236,542 ) $ 221,175 $ 212,379

Goodwill and Intangibles

Goodwill and Intangibles	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangibles	Goodwill and Intangible Assets Changes in the carrying amount of goodwill occurring during the nine months ended September 30, 2018 are as follows (in thousands): U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Total Goodwill at December 31, 2017 $ 218,525 $ 630,650 $ 84,487 $ 933,662 Goodwill adjustment associated with IMASCAP acquisition — (917 ) — (917 ) Foreign currency translation — (1,111 ) (10,258 ) (11,369 ) Goodwill at September 30, 2018 $ 218,525 $ 628,622 $ 74,229 $ 921,376 Goodwill is recognized for the excess of the purchase price over the fair value of net assets of businesses acquired. Goodwill is required to be tested for impairment at least annually. Unless circumstances otherwise dictate, the annual impairment test is performed in the fourth quarter annually. During the nine months ended September 30, 2018 , we revised opening balances acquired as a result of the IMASCAP acquisition, primarily for accounts receivable; other current assets; accrued expenses and other current liabilities; and deferred tax liabilities which resulted in a $0.9 million decrease in the preliminary value of goodwill determined as of December 14, 2017. See Note 3 for additional discussion of these adjustments. Following the December 2017 IMASCAP acquisition, foreign currency translation will be reported within the U.S. Upper Extremities segment. While the IMASCAP offices are located in France and the majority of their operations have a functional currency of the Euro, the results of the IMASCAP business are managed by U.S. Upper Extremities segment. The components of our identifiable intangible assets, net, are as follows (in thousands): September 30, 2018 December 31, 2017 Cost Accumulated amortization Cost Accumulated amortization Indefinite life intangibles: In-process research and development (IPRD) technology $ 5,178 $ 6,422 Finite life intangibles: Distribution channels 900 $ 835 900 $ 640 Completed technology 147,619 50,901 149,645 40,810 Licenses 6,547 1,706 5,268 1,530 Customer relationships 127,807 28,414 129,693 23,268 Trademarks 14,135 11,536 14,368 10,487 Non-compete agreements 3,111 2,315 3,964 2,603 Other 525 525 569 490 Total finite life intangibles 300,644 $ 96,232 304,407 $ 79,828 Total intangibles 305,822 310,829 Less: Accumulated amortization (96,232 ) (79,828 ) Intangible assets, net $ 209,590 $ 231,001 During September 2018, we received FDA clearance of AEQUALIS ® Adjustable Reversed Ext (AARE) (re-branded in 2016 to AEQUALIS ® Flex Revive), which resulted in a $1.0 million reclassification from IPRD technology to completed technology. Based on the total finite life intangible assets held at September 30, 2018 , we expect amortization expense of approximately $24.6 million in 2018 , $22.8 million in 2019 , $22.1 million in 2020 , $21.9 million in 2021 , and $21.9 million in 2022 .

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Lease Obligations	9 Months Ended
	Sep. 30, 2018
Long-term Debt and Capital Lease Obligations [Abstract]
Long Term Debt and Capital Lease Obligations	Debt and Capital Lease Obligations Debt and capital lease obligations consist of the following (in thousands): September 30, 2018 December 31, 2017 Capital lease obligations $ 22,875 $ 20,401 2023 Notes 542,575 — 2021 Notes 1 315,793 300,051 2020 Notes 1 170,798 513,014 Term Loan Facility 18,903 — Asset-based line of credit 21,549 53,645 Other debt 9,019 8,003 1,101,512 895,114 Less: Current portion 1 (514,930 ) (58,906 ) $ 586,582 $ 836,208 _______________________ 1 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes were classified as current liabilities as of September 30, 2018. The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash upon satisfaction of certain circumstances as described below. On or after August 15, 2019, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes were classified as current liabilities as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. 2023 Notes On June 28, 2018, WMG issued $675 million aggregate principal amount of the 2023 Notes pursuant to an indenture (2023 Notes Indenture), dated as of June 28, 2018, with The Bank of New York Mellon Trust Company, N.A., as trustee. The 2023 Notes are fully and unconditionally guaranteed by us on a senior unsecured basis. The 2023 Notes are referred to as "exchangeable" in the 2023 Notes Indenture because they were issued by WMG, not us. The 2023 Notes require interest to be paid at an annual rate of 1.625% semi-annually in arrears on each June 15 and December 15 and will mature on June 15, 2023 unless earlier converted or repurchased. The 2023 Notes are convertible, subject to certain conditions, solely into cash. The initial conversion rate for the 2023 Notes is 29.9679 ordinary shares (subject to adjustment as provided in the 2023 Notes Indenture) per $1,000 principal amount of the 2023 Notes (subject to, and in accordance with, the settlement provisions of the 2023 Notes Indenture), which is equal to an initial conversion price of approximately $33.37 per ordinary share. WMG may not redeem the 2023 Notes prior to the maturity date, and no “sinking fund” is available for the 2023 Notes, which means that WMG is not required to redeem or retire the 2023 Notes periodically. The holders of the 2023 Notes may convert their 2023 Notes at any time prior to the close of business on the business day immediately preceding December 15, 2022 solely into cash, in multiples of $1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2018 (and only during such calendar quarter), if the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2023 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after December 15, 2022 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2023 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2023 Notes, equal to the settlement amount as calculated under the 2023 Notes Indenture. If a fundamental change, as defined in the 2023 Notes Indenture, occurs, subject to certain conditions, holders of the 2023 Notes will have the option to require WMG to repurchase for cash all or a portion of their 2023 Notes at a repurchase price equal to 100% of the principal amount of the 2023 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the 2023 Notes Indenture. In addition, following a make-whole fundamental change, as defined in the 2023 Notes Indenture, that occurs prior to the maturity date, WMG, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2023 Notes in connection with such make-whole fundamental change. Our guarantee of the 2023 Notes is our senior unsecured obligation that ranks: (i) senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the guarantee; (ii) equal in right of payment to any of our unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. As a result of the issuance of the 2023 Notes, we recorded deferred financing charges of approximately $12.4 million , which are being amortized over the term of the 2023 Notes using the effective interest method. The 2023 Notes Exchange Derivative requires bifurcation from the 2023 Notes in accordance with ASC Topic 815, Derivatives and Hedging , and is accounted for as a derivative liability. See Note 6 for additional information regarding the 2023 Notes Exchange Derivative. The fair value of the 2023 Notes Exchange Derivative at the time of issuance of the 2023 Notes was $124.6 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2023 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2023 Notes using an effective interest rate of 6.06% . For the three and nine months ended September 30, 2018 , we recorded $4.9 million and $5.1 million of interest expense related to the amortization of the debt discount, respectively. The components of the 2023 Notes were as follows (in thousands): September 30, 2018 Principal amount of 2023 Notes $ 675,000 Unamortized debt discount (119,519 ) Unamortized debt issuance costs (12,906 ) Net carrying amount of 2023 Notes $ 542,575 The estimated fair value of the 2023 Notes was approximately $715.8 million at September 30, 2018 , based on a quoted price in an active market (Level 1). We and WMG entered into 2023 Notes Hedges in connection with the issuance of the 2023 Notes with two counterparties. The 2023 Notes Hedges, which are cash-settled, are generally intended to reduce WMG's exposure to potential cash payments that WMG would be required to make if holders elect to convert the 2023 Notes at a time when our ordinary share price exceeds the conversion price. However, in connection with certain events, including, among others, (i) a merger or other make-whole fundamental change; (ii) certain hedging disruption events, which may include changes in tax laws, an increase in the cost of borrowing our ordinary shares in the market or other material increases in the cost to the option counterparties of hedging the 2023 Note Hedges; (iii) our or WMG's failure to perform certain obligations under the 2023 Notes Indenture or under the 2023 Notes Hedges; (iv) certain defaults on our, WMG's or any our other subsidiary's indebtedness in excess of $25 million ; or (v) if we, WMG or any of our significant subsidiaries become insolvent or otherwise becomes subject to bankruptcy proceedings, the option counterparties have the discretion to terminate the 2023 Notes Hedges, which may reduce the effectiveness of the 2023 Notes Hedges. In addition, the option counterparties have broad discretion to make certain adjustments to the 2023 Notes Hedges and warrant transactions upon the occurrence of certain other events, including, among others, (i) any adjustment to the conversion rate of the 2023 Notes; or (ii) upon the announcement of certain significant corporate events, including events that may give rise to a termination event as described above, such as the announcement of a third-party tender offer. Any such adjustment may also reduce the effectiveness of the 2023 Note Hedges. The aggregate cost of the 2023 Notes Hedges was $141.3 million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 6 of the condensed consolidated financial statements for additional information regarding the 2023 Notes Hedges and the 2023 Notes Exchange Derivative. We also entered into warrant transactions in which we sold warrants that are initially exercisable into 20.2 million ordinary shares to the two option counterparties, subject to adjustment upon the occurrence of certain events, for an aggregate of $102.1 million . The strike price of the warrants is $40.86 per share, which was 50% above the last reported sale price of our ordinary shares on June 20, 2018. The warrants are expected to be net-share settled and exercisable over the 120 trading day period beginning on September 15, 2023. The warrant transactions will have a dilutive effect on our ordinary shares to the extent that the market value per ordinary share during such period exceeds the applicable strike price of the warrants. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to warrant transactions, which may increase our obligations under the warrant transactions. Aside from the initial payment of the $141.3 million premium in the aggregate to the two option counterparties and subject to the right of the option counterparties to terminate the 2023 Notes Hedges in certain circumstances, we do not expect to be required to make any cash payments to the option counterparties under the 2023 Notes Hedges and expect to be entitled to receive from the option counterparties cash, generally equal to the amount by which the market price per ordinary share exceeds the strike price of the convertible note hedging transactions during the relevant valuation period. The strike price under the 2023 Notes Hedges is initially equal to the conversion price of the 2023 Notes. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2023 Note Hedges, which may reduce the effectiveness of the 2023 Note Hedges. Additionally, if the market value per ordinary share exceeds the strike price on any settlement date under the warrant transaction, we will generally be obligated to issue to the option counterparties in the aggregate a number of shares equal in value to one percent of the amount by which the then-current market value of one ordinary share exceeds the then-effective strike price of each warrant, multiplied by the number of ordinary shares into which the 2023 Notes are initially convertible. We will not receive any additional proceeds if warrants are exercised. As described in more detail below, concurrently with the issuance and sale of the 2023 Notes, certain holders of the 2020 Notes exchanged their 2020 Notes for the 2023 Notes. 2021 Notes On May 20, 2016, we issued $395 million aggregate principal amount of the 2021 Notes pursuant to an indenture (2021 Notes Indenture), dated as of May 20, 2016 , between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021 Notes require interest to be paid at an annual rate of 2.25% semi-annually in arrears on each May 15 and November 15 and will mature on November 15, 2021 unless earlier converted or repurchased. The 2021 Notes are convertible, subject to certain conditions, solely into cash. The initial conversion rate for the 2021 Notes will be 46.8165 ordinary shares (subject to adjustment as provided in the 2021 Notes Indenture) per $1,000 principal amount of the 2021 Notes (subject to, and in accordance with, the settlement provisions of the 2021 Notes Indenture), which is equal to an initial conversion price of approximately $21.36 per ordinary share. We may not redeem the 2021 Notes prior to the maturity date, and no “sinking fund” is available for the 2021 Notes, which means that we are not required to redeem or retire the 2021 Notes periodically. The holders of the 2021 Notes may convert their 2021 Notes at any time prior to May 15, 2021 solely into cash, in multiples of $1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2016 (and only during such calendar quarter), if the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2021 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2021 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2021 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2021 Notes, equal to the settlement amount as calculated under the 2021 Notes Indenture. If we undergo a fundamental change, as defined in the 2021 Notes Indenture, subject to certain conditions, holders of the 2021 Notes will have the option to require us to repurchase for cash all or a portion of their 2021 Notes at a repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the 2021 Notes Indenture. In addition, following certain corporate transactions, we, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2021 Notes in connection with such corporate transaction. The 2021 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2021 Notes; (ii) equal in right of payment to any of our unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. As a result of the issuance of the 2021 Notes, we recorded deferred financing charges of approximately $7.3 million , which are being amortized over the term of the 2021 Notes using the effective interest method. As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 25, 2016. We currently do not expect significant conversions because the 2021 Notes currently trade at a premium to the as-converted value, and a converting holder would forego future interest payments. However, any conversions would reduce our cash resources. We believe that, in the event that holders elect to exercise the conversion option, our cash resources and access to additional borrowings would provide the necessary liquidity. The 2021 Notes Conversion Derivative requires bifurcation from the 2021 Notes in accordance with ASC Topic 815, Derivatives and Hedging , and is accounted for as a derivative liability. See Note 6 for additional information regarding the 2021 Notes Conversion Derivative. The fair value of the 2021 Notes Conversion Derivative at the time of issuance of the 2021 Notes was $117.2 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2021 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2021 Notes using an effective rate of 9.72% . For the three and nine months ended September 30, 2018 , we recorded $5.0 million and $14.8 million of interest expense, respectively, related to the amortization of the debt discount. For the three and nine months ended September 24, 2017 , we recorded $4.6 million and $13.4 million of interest expense, respectively, related to the amortization of the debt discount. The components of the 2021 Notes were as follows (in thousands): September 30, 2018 December 31, 2017 Principal amount of 2021 Notes $ 395,000 $ 395,000 Unamortized debt discount (74,552 ) (89,332 ) Unamortized debt issuance costs (4,655 ) (5,617 ) Net carrying amount of 2021 Notes $ 315,793 $ 300,051 The estimated fair value of the 2021 Notes was approximately $572.8 million at September 30, 2018 , based on a quoted price in an active market (Level 1). We entered into 2021 Notes Hedges in connection with the issuance of the 2021 Notes with two counterparties. The 2021 Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that we would be required to make if holders elect to convert the 2021 Notes at a time when our ordinary share price exceeds the conversion price. However, in connection with certain events, including, among others, (i) a merger or other make-whole fundamental change (as defined in the 2021 Notes Indenture); (ii) certain hedging disruption events, which may include changes in tax laws, an increase in the cost of borrowing our ordinary shares in the market or other material increases in the cost to the option counterparties of hedging the 2021 Note Hedges; (iii) our failure to perform certain obligations under the 2021 Notes Indenture or under the 2021 Notes Hedges; (iv) certain payment defaults on our existing indebtedness in excess of $25 million ; or (v) if we or any of our significant subsidiaries become insolvent or otherwise becomes subject to bankruptcy proceedings, the option counterparties have the discretion to terminate the 2021 Notes Hedges, which may reduce the effectiveness of the 2021 Notes Hedges. In addition, the option counterparties have broad discretion to make certain adjustments to the 2021 Notes Hedges and warrant transactions upon the occurrence of certain other events, including, among others, (i) any adjustment to the conversion rate of the 2021 Notes; or (ii) upon the announcement of certain significant corporate events, including events that may give rise to a termination event as described above, such as the announcement of a third-party tender offer. Any such adjustment may also reduce the effectiveness of the 2021 Note Hedges. The aggregate cost of the 2021 Notes Hedges was $99.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 6 of the condensed consolidated financial statements for additional information regarding the 2021 Notes Hedges and the 2021 Notes Conversion Derivative. We also entered into warrant transactions in which we sold warrants for an aggregate of 18.5 million ordinary shares to the two option counterparties, subject to adjustment, for an aggregate of $54.6 million . The strike price of the warrants is $30.00 per share, which was 69% above the last reported sale price of our ordinary shares on May 12, 2016 . The warrants are expected to be net-share settled and exercisable over the 100 trading day period beginning on February 15, 2022. The warrant transactions will have a dilutive effect on our ordinary shares to the extent that the market value per ordinary share during such period exceeds the applicable strike price of the warrants. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to warrant transactions, which may increase our obligations under the warrant transactions. Aside from the initial payment of the $99.8 million premium in the aggregate to the two option counterparties and subject to the right of the option counterparties to terminate the 2021 Notes Hedges in certain circumstances, we do not expect to be required to make any cash payments to the option counterparties under the 2021 Notes Hedges and expect to be entitled to receive from the option counterparties cash, generally equal to the amount by which the market price per ordinary share exceeds the strike price of the convertible note hedging transactions during the relevant valuation period. The strike price under the 2021 Notes Hedges is initially equal to the conversion price of the 2021 Notes. However, in connection with certain events, these option counterparties have the discretion to make certain adjustments to the 2021 Note Hedges, which may reduce the effectiveness of the 2021 Note Hedges. Additionally, if the market value per ordinary share exceeds the strike price on any settlement date under the warrant transaction, we will generally be obligated to issue to the option counterparties in the aggregate a number of shares equal in value to one percent of the amount by which the then-current market value of one ordinary share exceeds the then-effective strike price of each warrant, multiplied by the number of ordinary shares into which the 2021 Notes are initially convertible. We will not receive any additional proceeds if warrants are exercised. As described in more detail below, concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes and the 2020 Notes exchanged their 2017 Notes or 2020 Notes for the 2021 Notes. 2020 Notes On February 13, 2015 , WMG issued $632.5 million aggregate principal amount of the 2020 Notes pursuant to an indenture (2020 Notes Indenture), dated as of February 13, 2015 between WMG and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2020 Notes require interest to be paid semi-annually on each February 15 and August 15 at an annual rate of 2.00% , and mature on February 15, 2020 unless earlier converted or repurchased. The 2020 Notes were initially issued whereby they were convertible at the option of the holder, during certain periods and subject to certain conditions described below, solely into cash at an initial conversion rate of 32.3939 shares of WMG common stock per $1,000 principal amount of the 2020 Notes, subject to adjustment upon the occurrence of certain events, which represented an initial conversion price of approximately $30.87 per share of WMG common stock. On November 24, 2015, Wright Medical Group N.V. executed a supplemental indenture, fully and unconditionally guaranteeing, on a senior unsecured basis, WMG’s obligations relating to the 2020 Notes, changing the underlying reference securities from WMG common stock to Wright Medical Group N.V. ordinary shares and making a corresponding adjustment to the conversion price. From and after the effective time of the Wright/Tornier merger, (i) all calculations and other determinations with respect to the 2020 Notes previously based on references to WMG common stock are calculated or determined by reference to our ordinary shares, and (ii) the conversion rate (as defined in the 2020 Notes Indenture) for the 2020 Notes was adjusted to a conversion rate of 33.39487 ordinary shares (subject to adjustment as provided in the 2020 Notes Indenture) per $1,000 principal amount of the 2020 Notes, which represents a conversion price of approximately $29.94 per ordinary share (subject to, and in accordance with, the settlement provisions of the 2020 Notes Indenture). The 2020 Notes may not be redeemed by WMG prior to the maturity date, and no “sinking fund” is available for the 2020 Notes, which means that WMG is not required to redeem or retire the 2020 Notes periodically. The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash, in multiples of $1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015 (and only during such calendar quarter), if the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2020 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. The Wright/Tornier merger did not result in a conversion right for holders of the 2020 Notes. On or after August 15, 2019 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2020 Notes, equal to the settlement amount as calculated under the 2020 Notes Indenture. If WMG undergoes a fundamental change, as defined in the 2020 Notes Indenture, subject to certain conditions, holders of the 2020 Notes will have the option to require WMG to repurchase for cash all or a portion of their notes at a purchase price equal to 100% of the principal amount of the 2020 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as defined in the 2020 Notes Indenture. In addition, following certain corporate transactions, WMG, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2020 Notes in connection with such corporate transaction. The 2020 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of WMG's indebtedness that is expressly subordinated in right of payment to the 2020 Notes; (ii) equal in right of payment to any of WMG's unsecured indebtedness that is not so subordinated; (iii) effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and (iv) structurally junior to all indebtedness and other liabilities (including trade payables) of WMG's subsidiaries. In conjunction with the issuance of the 2020 Notes, we recorded deferred financing charges of approximately $18.1 million , which are being amortized over the term of the 2020 Notes using the effective interest method. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes and the fair value of the 2020 Notes Conversion Derivatives were classified as current liabilities and the fair value of the 2020 Notes Hedges was classified as current assets as of September 30, 2018. The respective balances were all classified as long-term as of December 31, 2017. The 2020 Notes Conversion Derivative requires bifurcation from the 2020 Notes in accordance with ASC Topic 815, Derivatives and Hedging, and is accounted for as a derivative liability. See Note 6 of the condensed consolidated financial statements for additional information regarding the 2020 Notes Conversion Derivative. The fair value of the 2020 Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million and was recorded as original debt discount for purposes of accounting for the debt component of the 2020 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2020 Notes based upon an effective rate of 8.54% . For the three and nine months ended September 30, 2018 , we recorded $2.4 million and $16.7 million of interest expense, respectively, related to the amortization of the debt discount. For the three and nine months ended September 24, 2017 , we recorded $6.9 million and $20.3 million of interest expense, respectively, related to the amortization of the debt discount. Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2020 Notes exchanged approximately $45 million aggregate principal amount of their 2020 Notes for the 2021 Notes. For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $990.00 principal amount of the 2021 Notes (subject to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2020 Notes and the rounded amount. As a result of this note exchange and retirement of $45 million aggregate principal amount of the 2020 Notes, we recognized approximately $9.3 million for the write-off of related pro-rata unamortized deferred financing fees and debt discount. Concurrently with the issuance and sale of the 2023 Notes, certain holders of the 2020 Notes exchanged approximately $400.9 million aggregate principal amount of their 2020 Notes for the 2023 Notes. For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $1,138.70 principal amount of the 2023 Notes (subject to rounding down to the nearest $1,000 principal amount of the 2023 Notes for each exchanging investor, the difference being referred as the rounded amount) to the investor. As a result of this note exchange and retirement of $400.9 million aggregate principal amount of the 2020 Notes, we recognized approximately $39.9 million for the write-off of related pro-rata unamortized deferred financing fees and debt discount within “Other (income) expense, net” in our condensed consolidated statements of operations during the three months ended July 1, 2018. The components of the 2020 Notes were as follows (in thousands): September 30, 2018 December 31, 2017 Principal amount of 2020 Notes $ 186,589 $ 587,500 Unamortized debt discount (14,081 ) (66,418 ) Unamortized debt issuance costs (1,710 ) (8,068 ) Net carrying amount of 2020 Notes $ 170,798 $ 513,014 The estimated fair value of the 2020 Notes was approximately $204.7 million at September 30, 2018 , based on a quoted price in an active market (Level 1). WMG entered into the 2020 Notes Hedges in connection with the issuance of the 2020 Notes with three option counterparties. See Note 6 of the condensed consolidated financial statements for additional information on the 2020 Notes Hedges. The 2020 Notes Hedges, which are cash-settled, are generally intended to reduce WMG's exposure to potential cash payments that WMG would be required to make if holders elect to convert the 2020 Notes at a time when our ordinary share price exceeds the conversion price. However, in connection with certain events, includin

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Sep. 30, 2018
Accumulated Other Comprehensive Income [Abstract]
Comprehensive Income (Loss), Note	Accumulated Other Comprehensive Income (AOCI) Other comprehensive income (OCI) includes certain gains and losses that under US GAAP are included in comprehensive income (loss) but are excluded from net loss as these amounts are initially recorded as an adjustment to shareholders’ equity. Amounts in OCI may be reclassified to net loss upon the occurrence of certain events. For the nine months ended September 30, 2018 and September 24, 2017 , OCI was comprised solely of foreign currency translation adjustments. Changes in AOCI for the nine months ended September 30, 2018 and September 24, 2017 were as follows (in thousands): Nine months ended September 30, 2018 Currency translation adjustment Balance at December 31, 2017 $ 22,290 Other comprehensive loss (19,642 ) Balance at September 30, 2018 $ 2,648 Nine months ended September 24, 2017 Currency translation adjustment Balance at December 25, 2016 $ (19,461 ) Other comprehensive income 44,362 Balance at September 24, 2017 $ 24,901

Changes in Stockholders' Equity

Changes in Stockholders' Equity (Notes)	9 Months Ended
	Sep. 30, 2018
Changes in Stockholders' Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Changes in Shareholders' Equity The following table provides an analysis of changes in each balance sheet caption of shareholders’ equity for the nine months ended September 30, 2018 and September 24, 2017 (in thousands, except share data): Nine months ended September 30, 2018 Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income (loss) Total shareholders' equity Number of shares Amount Balance at December 31, 2017 105,807,424 $ 3,896 $ 1,971,347 $ (1,408,837 ) $ 22,290 $ 588,696 2018 Activity: Net loss — — — (135,737 ) — (135,737 ) Foreign currency translation — — — — (19,642 ) (19,642 ) Issuances of ordinary shares 556,827 20 10,955 — — 10,975 Shares issued for public offering ( Note 12 ) 18,248,932 641 422,371 — — 423,012 Vesting of restricted stock units 452,057 16 (16 ) — — — Share-based compensation — — 18,238 — — 18,238 Issuance of stock warrants, net of repurchases and equity issuance costs — — 72,956 — — 72,956 Balance at September 30, 2018 125,065,240 $ 4,573 $ 2,495,851 $ (1,544,574 ) $ 2,648 $ 958,498 Nine months ended September 24, 2017 Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive (loss) income Total shareholders' equity Number of shares Amount Balance at December 25, 2016 103,400,995 $ 3,815 $ 1,908,749 $ (1,206,239 ) $ (19,461 ) $ 686,864 2017 Activity: Net loss — — — (231,731 ) — (231,731 ) Foreign currency translation — — — — 44,362 44,362 Issuances of ordinary shares 1,217,088 40 24,788 — — 24,828 Vesting of restricted stock units 393,595 13 (13 ) — — — Share-based compensation — — 14,193 — — 14,193 Balance at September 24, 2017 105,011,678 $ 3,868 $ 1,947,717 $ (1,437,970 ) $ 24,901 $ 538,516

Earnings per share (Notes)

Earnings per share (Notes)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Capital Stock and Earnings Per Share We are authorized to issue up to 320 million ordinary shares, each share with a par value of three Euro cents ( €0.03 ). We had 125.1 million and 105.8 million ordinary shares issued and outstanding as of September 30, 2018 and December 31, 2017 , respectively. On August 27, 2018, we entered into an underwriting agreement with J.P. Morgan, relating to the registered public offering of 18,248,932 ordinary shares, at an initial price to the public of $24.60 per share, for a total price of $448.9 million . The net proceeds to us were $423.0 million , after deducting underwriting discounts and commissions of $25.4 million and offering costs of $0.5 million . The offering closed on August 30, 2018. The proceeds were used to fund the purchase price of the Cartiva acquisition which closed on October 10, 2018, as well as costs and expenses related thereto. See Note 15 for additional details related to the Cartiva acquisition. FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings per share is calculated based on the weighted-average number of ordinary shares outstanding during the period. Diluted earnings per share is calculated to include any dilutive effect of our ordinary share equivalents. For the three and nine months ended September 30, 2018 and September 24, 2017 , our ordinary share equivalents consisted of stock options, restricted stock units, performance share units, and warrants. The dilutive effect of the stock options, restricted stock units, performance share units, and warrants is calculated using the treasury-stock method. We had outstanding options to purchase 10.4 million ordinary shares, 1.3 million restricted stock units, and 0.2 million performance stock units, assuming target performance, at September 30, 2018 and outstanding options to purchase 10.4 million ordinary shares, 1.4 million restricted stock units, and 0.1 million performance stock units, assuming target performance, at September 24, 2017 . We had outstanding net-share settled warrants on the 2020 Notes of 6.2 million and 19.6 million ordinary shares at September 30, 2018 and September 24, 2017 , respectively. We also had net-share settled warrants on the 2021 Notes of 18.5 million ordinary shares at September 30, 2018 and September 24, 2017 . Finally, we had net-share settled warrants on the 2023 Notes of 20.2 million ordinary shares at September 30, 2018 . None of the options, restricted stock units, performance share units, or warrants were included in the calculation of diluted net loss from continuing operations per share, diluted net (loss) income from discontinued operations per share, and diluted net loss per share for the three and nine months ended September 30, 2018 or September 24, 2017 , because we recorded a net loss from continuing operations for all periods. Including these instruments would be anti-dilutive as the net loss from continuing operations is the control number in determining whether those potential common shares are dilutive or anti-dilutive. The weighted-average number of ordinary shares outstanding for basic and diluted earnings per share purposes is as follows (in thousands): Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 Weighted-average number of ordinary shares outstanding-basic and diluted 113,043 104,836 108,348 104,292

Commitments and Contingencies (

Commitments and Contingencies (Notes)	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Legal Contingencies The legal contingencies described in this footnote relate primarily to WMT, an indirect subsidiary of Wright Medical Group N.V., and are not necessarily applicable to Wright Medical Group N.V. or other affiliated entities. Maintaining separate legal entities within our corporate structure is intended to ring-fence liabilities. We believe our ring-fenced structure should preclude corporate veil-piercing efforts against entities whose assets are not associated with particular claims. As described below, our business is subject to various contingencies, including patent and other litigation, product liability claims, and a government inquiry. These contingencies could result in losses, including damages, fines, or penalties, any of which could be substantial, as well as criminal charges. Although such matters are inherently unpredictable, and negative outcomes or verdicts can occur, we believe we have significant defenses in all of them and are vigorously defending all of them. However, we could incur judgments, pay settlements, or revise our expectations regarding the outcome of any matter. Such developments, if any, could have a material adverse effect on our results of operations in the period in which applicable amounts are accrued, or on our cash flows in the period in which amounts are paid, however, unless otherwise indicated, we do not believe any of them will have a material adverse effect on our financial position. Our legal contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss or the measurement of a loss can be complex. We have accrued for losses that are both probable and reasonably estimable. Unless otherwise indicated, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate. Unanticipated events and circumstances may occur that could cause us to change our estimates and assumptions. Governmental Inquiries On August 3, 2012, we received a subpoena from the United States Attorney's Office for the Western District of Tennessee requesting records and documentation relating to our PROFEMUR ® series of hip replacement devices. The subpoena covers the period from January 1, 2000 to August 2, 2012. We will continue to cooperate as required. Patent Litigation On September 23, 2014, Spineology filed a patent infringement lawsuit, Case No. 0:14-cv-03767, in the U.S. District Court in Minnesota, alleging that our X-REAM ® bone reamer infringes U.S. Patent No. RE42,757 entitled “EXPANDABLE REAMER.” In January 2015, on the deadline for service of its complaint, Spineology dismissed its complaint without prejudice and filed a new, identical complaint. We filed an answer to the new complaint with the Court on April 27, 2015. The Court conducted a Markman hearing on March 23, 2016. Mediation was held on August 11, 2016, but no agreement could be reached. The Court issued a Markman decision on August 30, 2016, in which it found all asserted product claims invalid as indefinite under applicable patent laws and construed several additional claim terms. The parties completed fact and expert discovery with respect to the remaining asserted method claims. We filed a motion for summary judgment of non-infringement of the remaining asserted patent claims and motions to exclude testimony from Spineology’s technical and damages experts. Spineology filed a motion for summary judgment of infringement. On July 25, 2017, the Court granted our motion for summary judgment of non-infringement; denied Spineology’s motion for summary judgment of infringement; and denied all remaining motions as moot. The Court also entered judgment in our favor and against Spineology on all issues. Spineology appealed the judgment to the U.S. Court of Appeals for the Federal Circuit and on July 6, 2018, the Court of Appeals affirmed the judgment of non-infringement in our favor and directed the District Court to enter judgment of non-infringement as to all of Spineology’s asserted patent claims. On September 6, 2018, the Court of Appeals denied Spineology’s petition for rehearing and, on September 18, 2018, the District Court entered final judgment of non-infringement. On September 13, 2016, we filed a civil action, Case No. 2:16-cv-02737-JPM, against Spineology in the U.S. District Court for the Western District of Tennessee alleging breach of contract, breach of implied warranty against infringement, and seeking a judicial declaration of indemnification from Spineology for patent infringement claims brought against us stemming from our sale and/or use of certain expandable reamers purchased from Spineology. Spineology filed a motion to dismiss on October 17, 2016, but withdrew the motion on November 28, 2016. On December 7, 2016, Spineology filed an answer to our complaint and counterclaims, including counterclaims relating to a 2004 non-disclosure agreement between Spineology and WMT. On December 28, 2016, we filed a motion to dismiss the counterclaims relating to that 2004 agreement. On January 4, 2017, Spineology filed a motion for summary judgment on certain claims set forth in our complaint. We opposed that motion. On January 27, 2017, we filed a motion for summary judgment on certain issues pertaining to our indemnification claims. Spineology opposed that motion. On July 7, 2017, the Court extended the deadlines for completing discovery until after it ruled on those pending motions. On August 29, 2017, the Court ruled on the motions to dismiss and for summary judgment. In view of that decision, on September 22, 2017, the parties stipulated to, and the Court entered, a judgment that effectively ended the case in a draw. We appealed the judgment as to our claims against Spineology to the U.S. Court of Appeals for the Sixth Circuit and oral argument occurred on August 2, 2018. On August 24, 2018, the Court of Appeals ruled in our favor on our breach of contract claim and remanded the case to the District Court for further proceedings. Spineology did not appeal the District Court’s dismissal of its contract counterclaim. Product Liability We have received claims for personal injury against us associated with fractures of our PROFEMUR ® titanium modular neck product (PROFEMUR ® Claims). As of September 30, 2018, there were approximately 18 unresolved pending U.S. lawsuits and approximately 57 unresolved pending non-U.S. lawsuits alleging such claims. The overall fracture rate for the product is low and the fractures appear, at least in part, to relate to patient demographics. Beginning in 2009, we began offering a cobalt-chrome version of our PROFEMUR ® modular neck, which has greater strength characteristics than the alternative titanium version. Historically, we have reflected our liability for these claims as part of our standard product liability accruals on a case-by-case basis. However, during the fiscal quarter ended September 30, 2011, as a result of an increase in the number and monetary amount of these claims, management estimated our liability to patients in the United States and Canada who have previously required a revision following a fracture of a PROFEMUR ® titanium modular neck, or who may require a revision in the future. Management has estimated that this aggregate liability is $18.2 million . We have classified $11.7 million of this liability in “Accrued expenses and other current liabilities,” as we expect to pay such claims within the next twelve months, and $6.5 million as non-current in “Other liabilities” on our consolidated balance sheet. We expect to pay the majority of these claims within the next three years. Any claims associated with this product outside of the United States and Canada, or for any other products, will be managed as part of our standard product liability accrual methodology on a case-by-case basis. We have maintained product liability insurance coverage on a claims-made basis. During the fiscal quarter ended March 31, 2013, we received a customary reservation of rights from our primary product liability insurance carrier asserting that present and future claims related to fractures of our PROFEMUR ® titanium modular neck hip products and which allege certain types of injury (Titanium Modular Neck Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The effect of this coverage position would be to place Titanium Modular Neck Claims into a single prior policy year in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agreed with the assertion that the Titanium Modular Neck Claims should be treated as a single occurrence, but notified the carrier that it disputed the carrier's selection of available policy years. During the second quarter of 2013, we received confirmation from the primary carrier confirming their agreement with our policy year determination. Based on our insurer's treatment of Titanium Modular Neck Claims as a single occurrence, we increased our estimate of the total probable insurance recovery related to Titanium Modular Neck Claims by $19.4 million and recognized such additional recovery as a reduction to our selling, general and administrative expenses for the fiscal quarter ended March 31, 2013, within results of discontinued operations. In the fiscal quarter ended June 30, 2013, we received payment from the primary insurance carrier of $5 million . In the fiscal quarter ended September 30, 2013, we received payment of $10 million from the next insurance carrier in the tower. We requested, but did not receive, payment of the remaining $25 million from the third insurance carrier in the tower for that policy period. The policies with the second and third carrier in this tower are “follow form” policies and management believed the third carrier should follow the coverage position taken by the primary and secondary carriers. On September 29, 2015, that third carrier asserted that the terms and conditions identified in its reservation of rights would preclude coverage for the Titanium Modular Neck Claims. Pursuant to applicable accounting standards, we reduced our insurance receivable balance for this claim to $0 and recorded a $25 million charge within “Net loss from discontinued operations” during the fiscal year ended December 27, 2015. We strongly disputed the carrier's position and, in accordance with the dispute resolution provisions of the policy, initiated an arbitration proceeding in London, England seeking payment of these funds. The arbitration proceeding was completed on February 15, 2018 and, on April 11, 2018, the arbitration tribunal issued its ruling. Thereafter, we and the insurance carrier agreed to resolve the entire matter in exchange for a single lump sum payment by the carrier to us in the amount of $30.75 million , representing the full policy limits of $25 million plus an additional $5.75 million for legal costs and interest. We received payment of this sum from the carrier on May 8, 2018. This insurance recovery is reflected within our results of discontinued operations for the quarter ended July 1, 2018. We are aware that MicroPort has recalled a certain size of its cobalt chrome modular neck product as a result of alleged fractures. As of September 30, 2018, there were seven pending U.S. lawsuits and five pending non-U.S. lawsuits against us alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These claims will be managed as part of our standard product liability accrual methodology on a case-by-case basis. Claims for personal injury have also been made against us associated with our metal-on-metal hip products (primarily the CONSERVE ® product line). The pre-trial management of certain of these claims was consolidated in the federal court system, in the United States District Court for the Northern District of Georgia under multi-district litigation (MDL) and certain other claims by the Judicial Counsel Coordinated Proceedings in state court in Los Angeles County, California (JCCP) in state court in Los Angeles County, California (collectively the Consolidated Metal-on-Metal Claims). Pursuant to previously disclosed settlement agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP described below, the MDL and JCCP were closed to new cases effective October 18, 2017 and October 31, 2017, respectively. Excluding claims resolved in the settlement agreements described below, as of September 30, 2018, there were approximately 129 unresolved metal-on-metal hip cases pending in the U.S. This number includes cases ineligible for settlement, cases which opted out of settlement, post-settlement cases, tolled cases, and existing state court cases that were not part of the MDL or JCCP. As of September 30, 2018, we estimate there also were pending approximately 34 non-U.S. metal-on metal cases and 34 unresolved modular neck U.S. cases and no non-U.S. cases alleging claims related to the release of metal ions. We also estimate that as of September 30, 2018 there were approximately 535 non-revision claims either dismissed or awaiting dismissal from the MDL and JCCP pursuant to the terms of the settlement agreements. Although there is a limited time period during which dismissed non-revision claims may be refiled, it is presently unclear how many non-revision claimants will elect to do so. As of September 30, 2018, no dismissed non-revision cases have been refiled. We believe we have data that supports the efficacy and safety of our hip products. Every hip implant case, including metal-on-metal hip cases, involves fundamental issues of law, science, and medicine that often are uncertain, that continue to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and issues include medical causation, individual patient characteristics, surgery specific factors, statutes of limitation, and the existence of actual, provable injury. On November 1, 2016, WMT entered into the MSA with Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims associated with CONSERVE ® , DYNASTY ® and LINEAGE ® products that meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million . The $240 million settlement amount is a maximum settlement based on the pool of 1,292 specific, existing claims comprised of an identified mix of CONSERVE ® , DYNASTY ® and LINEAGE ® products (Initial Settlement Pool), with a value assigned to each product type, resulting in a total settlement of $240 million for the 1,292 claims in the Initial Settlement Pool. Actual settlements paid to individual claimants are determined under the claims administration procedures contained in the MSA and may be more or less than the amounts used to calculate the $240 million settlement for the 1,292 claims in the Initial Settlement Pool. However in no event will variations in actual settlement amounts payable to individual claimants affect WMT’s maximum settlement obligation of $240 million or the manner in which it may be reduced due to opt outs, final product mix, or elimination of ineligible claims. Claims in the Initial Settlement Pool that were ineligible due to failure to meet the eligibility criteria of the MSA were replaced with new eligible claims involving the same product, so that the number and mix of claims in the final settlement pool (before opt-outs) (Final Settlement Pool) equaled the number and mix of claims in the Initial Settlement Pool. Additionally, where DYNASTY ® or LINEAGE ® claims in the Final Settlement Pool were determined to have been misidentified as CONSERVE ® claims, or vice versa, the total settlement amount was adjusted based on the value for each product type (not to exceed $240 million ). The MSA contains specific eligibility requirements and establishes procedures for proof and administration of claims, negotiation, and execution of individual settlement agreements, determination of the final total settlement amount, and funding of individual settlement amounts by WMT. Eligibility requirements include, without limitation, that the claimant has a claim pending or tolled in the MDL or JCCP, that the claimant has undergone a revision surgery within eight years of the original implantation surgery, and that the claim has not been identified by WMT as having possible statute of limitation issues. Claimants who have had bilateral revision surgeries will be counted as two claims but only to the extent both claims separately satisfy all eligibility criteria. The MSA includes a 95% opt-in requirement, meaning the MSA could have been terminated by WMT prior to any settlement disbursement if claimants holding greater than 5% of eligible claims in the Final Settlement Pool elected to “opt-out” of the settlement. WMT has confirmed that of the 1,292 eligible claims, 1,279 opted to participate in the settlement and 13 opted out, resulting in a final opt-in percentage of approximately 99% , well in excess of the required 95% threshold. On March 2, 2017, WMT agreed to replace the 13 opt-out claims with 13 additional claims that would have been eligible to participate in the MSA but for the 1,292 claim limit, bringing the total MSA settlement to the maximum limit of $240 million to settle 1,292 claims. Due to apparent demand from additional claimants excluded from settlement because of the 1,292 claims ceiling, but otherwise eligible for participation, on May 5, 2017, WMT agreed to settle an additional 53 such claims, on terms substantially identical to the MSA settlement terms, for a maximum additional settlement amount of $9.4 million . During 2016, WMT escrowed $150 million to secure its obligations under the MSA, all of which had been disbursed as of December 31, 2017. As additional security, Wright Medical Group N.V., the indirect parent company of WMT, agreed to guarantee WMT’s obligations under the MSA. On October 3, 2017, WMT entered into the Second Settlement Agreements with the Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the Second Settlement Agreements, the parties agreed to settle 629 specifically identified CONSERVE ® , DYNASTY ® and LINEAGE ® claims that meet the eligibility requirements of the Second Settlement Agreements and are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a maximum settlement amount of $89.75 million . The comprehensive settlement amount was contingent on WMT’s recovery of new insurance proceeds totaling at least $35 million from applicable insurance carriers by December 31, 2017. On December 29, 2017, WMT entered into a First Amendment to the Third Settlement Agreement pursuant to which the deadline for the recovery of new insurance proceeds totaling at least $35 million from applicable insurance carriers was extended through February 28, 2018 and, on February 23, 2018, WMT entered into a Second Amendment to the Third Settlement Agreement pursuant to which the deadline was extended through March 30, 2018. On March 29, 2018, WMT entered into a Third Amendment to the Third Settlement Agreement which eliminated the contingency and gave WMT the option, by September 30, 2018, to either pay or make available for payment the then outstanding deficit on the insurance contingency or transfer to eligible claimants WMT’s claims against the insurance carriers with whom WMT has not settled, and pay or make available for payment such insurance deficit in March 2019, subject to the right to recover these funds from any plaintiff recoveries from carriers plus ten percent interest, plus an additional $5 million in costs, in each case after recovery by plaintiffs’ counsel of costs and fees. In connection with such transfer agreement, WMT would also enter into a stipulated judgment in the amount of $541 million , which judgment would not be recoverable against WMT or its affiliates. On September 27, 2018, WMT elected not to transfer WMT’s claims against the insurance carriers with whom WMT has not settled. As of September 30, 2018, certain of the insurance carriers have contributed $21.9 million of funds applicable against the $35 million contingency, leaving a $13.1 million deficit. The $89.75 million settlement amount is a maximum settlement based on the pool of 629 specific, existing claims comprised of an identified mix of CONSERVE ® , DYNASTY ® and LINEAGE ® products (Second Settlement Initial Settlement Pool), with a value assigned to each product type. Actual settlements paid to individual claimants will be determined under the claims administration procedures contained in the Second Settlement Agreements and may be more or less than the amounts used to calculate the $89.75 million settlement for the 629 claims in the Second Settlement Initial Settlement Pool. However in no event will variations in actual settlement amounts payable to individual claimants affect WMT’s maximum settlement obligation of $89.75 million or the manner in which it may be reduced due to opt outs, final product mix, or elimination of ineligible claims. The total maximum settlement amount of $89.75 million is allocated among the following three tranches: (1) Tranche 1: $7.9 million to settle 49 additional claims that would have been eligible to participate in the MSA but for the claim limit contained therein, which amount will be funded as such claims are settled; (2) Tranche 2: $5.1 million to settle 39 eligible claims of the oldest claimants (by age), which amount will be funded as such claims are settled; and (3) Tranche 3: $76.75 million to settle 511 eligible claims pending or tolled in the MDL and JCCP existing as of June 30, 2017, and 30 new eligible claims which were presented between July 1, 2017 and October 1, 2017. Settlement funds for Tranche 3 were or will be made available for payment as follows: $45 million (less the remaining insurance deficit, which was $13.1 million ) on June 30, 2018, the remaining insurance deficit ( $13.1 million ) by September 30, 2018, and the balance by September 30, 2019. Actual funding has not yet occurred as claims are still in the administration process. The Second Settlement Agreements contain specific eligibility requirements and establish procedures for proof and administration of claims, negotiation, and execution of individual settlement agreements, determination of the final total settlement amount, and funding of individual settlement amounts by WMT. Eligibility requirements include, without limitation, that the claimant has a claim pending or tolled in the MDL or JCCP and that, with limited exceptions, the claimant has undergone a revision surgery. Claimants who have had bilateral revision surgeries will be counted as two claims but only to the extent both claims separately satisfy all eligibility criteria. Each of the Second Settlement Agreements includes a 95% opt-in requirement, meaning WMT could have terminated either Settlement Agreement prior to any settlement disbursement if claimants holding greater than 5% of eligible claims in Tranches 1 and 2, collectively, or claimants holding greater than 5% of eligible claims in Tranche 3, elected to “opt-out” of the settlement. On January 2, 2018, WMT received notification that 100% of the claimants in Tranches 1 and 2 opted-in. WMT reviewed proof of claim documentation for these claimants and confirmed a final opt-in percentage of 100%. On or about May 1, 2018, WMT received notice from plaintiffs that the 95% opt-in threshold had also been met for Tranche 3. WMT reviewed proof of claim documentation for Tranche 3 claimants and confirmed that the 95% opt-in threshold had been met. On July 31, 2018, WMT confirmed a final opt-in percentage of 100% for Tranche 3. While the Second Settlement Agreements did not require WMT to escrow any amount to secure its obligations thereunder, as additional security, Wright Medical Group N.V., the indirect parent company of WMT, agreed to guarantee WMT’s obligations under the Second Settlement Agreements. The MSA (which reference includes the supplemental settlements described above) and the Second Settlement Agreements were entered into solely as a compromise of the disputed claims being settled and are not evidence that any claim has merit nor are they an admission of wrongdoing or liability by WMT. WMT will continue to vigorously defend metal-on-metal hip claims not settled pursuant to the above agreements. The Second Settlement Agreements are contingent upon the dismissal without prejudice of pending and tolled claims in the MDL and JCCP that do not meet the inclusion criteria of the MDL or JCCP. Additionally, the Second Settlement Agreements are contingent upon the dismissal without prejudice of all remaining non-revision claims in the MDL and JCCP (presently estimated to number approximately 535 claims either dismissed or awaiting dismissal), pursuant to a tolling agreement that tolls applicable statutes of limitation and repose for three months from a revision of the products or determination that a revision of the products is necessary. The MDL and JCCP courts have both entered orders closing these proceedings to new claims. As a result of entering into the Second Settlement Agreements during the third quarter of 2017, we recorded an additional accrual of $82.7 million for the 629 matters included within the settlement and for matters that have the same eligibility criteria. As of September 30, 2018, our accrual for metal-on-metal claims totaled $105.6 million , of which $88.8 million is included in our consolidated balance sheet within “Accrued expenses and other current liabilities” and $16.8 million is included within “Other liabilities.” Our accrual is based on (i) case by case accruals for specific cases where facts and circumstances warrant, and (ii) the implied settlement values for eligible claims under the MSA or Second Settlement Agreements. We are unable to reasonably estimate the high-end of a possible range of loss for claims which elected to opt-out of the MSA or Second Settlement Agreements. Claims we can confirm would meet MSA or Second Settlement Agreements eligibility criteria but are excluded from the settlements due to the maximum settlement cap, or because they are cases not part of the MDL or JCCP, have been accrued as of the respective settlement rates. Due to the general uncertainties surrounding all metal-on metal claims as noted above, as well as insufficient information about individual claims, we are presently unable to reasonably estimate a range of loss for future claims; hence we have not accrued for these claims at the present time. We continue to believe the high-end of a possible range of loss for existing revision claims that do not meet eligibility criteria of the MSA or Second Settlement Agreements will not, on an average per case basis, exceed the average per case accrual we take for revision claims we can confirm do meet eligibility criteria of the MSA or Second Settlement Agreements, as applicable. Future claims will be evaluated for accrual on a case by case basis using the accrual methodologies described above (which could change if future facts and circumstances warrant). The first state court metal-on-metal hip trial not part of the MDL or JCCP commenced on October 24, 2016, in St. Louis, Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff appealed, and the appellate court heard oral argument on November 8, 2017. On February 20, 2018, the Missouri Court of Appeals, Eastern District, denied the plaintiff’s appeal and upheld the verdict of the trial court. The plaintiff’s time for seeking any further relief from the verdict has lapsed and this matter is closed. We have maintained product liability insurance coverage on a claims-made basis. During the fiscal quarter ended September 30, 2012, we received a customary reservation of rights from our primary product liability insurance carrier asserting that certain present and future claims which allege certain types of injury related to our CONSERVE ® metal-on-metal hip products (CONSERVE ® Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The effect of this coverage position would be to place CONSERVE ® Claims into a single prior policy year in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees that there is insurance coverage for the CONSERVE ® Claims, but has notified the carrier that it disputes the carrier's characterization of the CONSERVE ® Claims as a single occurrence. In June 2014, Travelers, which was an excess carrier in our coverage towers across multiple policy years, filed a declaratory judgment action in Tennessee state court naming us and certain of our other insurance carriers as defendants and asking the court to rule on the rights and responsibilities of the parties with regard to the CONSERVE ® Claims. Among other things, Travelers appeared to dispute our contention that the CONSERVE ® Claims arise out of more than a single occurrence thereby triggering multiple policy periods of coverage. Travelers further sought a determination as to the applicable policy period triggered by the alleged single occurrence. We filed a separate lawsuit in state court in California for declaratory judgment against certain carriers and breach of contract against the primary carrier and moved to dismiss or stay the Tennessee action on a number of grounds, including that California is the most appropriate jurisdiction. During the third quarter of 2014, the California Court granted Travelers' motion to stay our California action. On October 28, 2016, WMT and Wright Medical Group, Inc. (Wright Entities) entered into a Settlement Agreement, Indemnity and Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three insurance carriers, namely Columbia Casualty Company, Travelers and AXIS Surplus Lines Insurance Company (collectively, the Three Settling Insurers), pursuant to which the Three Settling Insurers paid WMT an aggregate of $60 million (in addition to $10 million previously paid by Columbia) in a lump sum. This amount is in full satisfaction of all potential liability of the Three Settling Insurers relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in the MDL and the JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described above. As part of the settlement with the Three Settling Insurers, the Three Settling Insurers bought back from WMT their policies in the five policy years beginning with the August 1, 2007- August 1, 2008 policy year (Repurchased Policy Years). Consequently, the Wright Entities have no further coverage from the Three Settling Insurers for any present or future claims falling in the Repurchased Policy Years, or any other period in which a released claim is asserted. Additionally, the Insurance Settlement Agreement contains a so-called most favored nation provision which could require us to refund a pro rata portion of the settlement amount if we voluntarily enter into a settlement with the remaining carriers in the Repurchased Policy Years on certain terms more favorable than analogous terms in the Insurance Settlement Agreement. The amount due to the Wright Entities under the Insurance Settlement Agreement was paid in the fourth quarter of 2016 and the Three Settling Insurers have been dismissed from the Tennessee action. On December 13, 2016, we filed a motion in the Tennessee action described above to include allegations of bad faith against the primary insurance carrier. The motion was subsequently amended on February 8, 2017 to add similar bad faith claims against the remaining excess carriers. On April 13, 2017, the Court denied our motion, without prejudice to our right to re-assert the motion at a later time. On August 29, 2017, we refiled the motion to add a bad faith claim against the primary and excess insurance carriers. The Court granted our motion on October 19, 2017 and, on October 23, 2017, we filed amended cross-claims allegi

Segment Data

Segment Data	9 Months Ended
	Sep. 30, 2018
Segment Data [Abstract]
Segment Data	Segment Information Our management, including our Chief Executive Officer, who is our chief operating decision maker, manages our operations as three operating business segments: U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics. We determined that each of these operating segments represented a reportable segment. Our Chief Executive Officer reviews financial information at the operating segment level to allocate resources and to assess the operating results and performance of each segment. Our U.S. Lower Extremities & Biologics segment consists of our operations focused on the sale in the United States of our lower extremities products, such as joint implants and bone fixation devices for the foot and ankle, and our biologics products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. Our U.S. Upper Extremities segment consists of our operations focused on the sale in the United States of our upper extremities products, such as joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand, and products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and other ancillary products. As the IMASCAP operations will be managed by the U.S. Upper Extremities management team, results of operations and assets related to IMASCAP will be included within the U.S. Upper Extremities segment. Our International Extremities and Biologics segment consists of our operations focused on the sale outside the United States of all lower and upper extremities products, including associated biologics products. Management measures segment profitability using an internal operating performance measure that excludes the impact of transaction and transition costs associated with acquisitions, as such items are not considered representative of segment results. We have determined that each reportable segment represents a reporting unit and, in accordance with ASC 350, requires an allocation of goodwill to each reporting unit. Selected financial information related to our segments is presented below for the three months ended September 30, 2018 and September 24, 2017 (in thousands): Three months ended September 30, 2018 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate 1 Total Net sales from external customers $ 79,296 $ 66,269 $ 48,541 $ — $ 194,106 Depreciation expense 2,474 2,836 3,366 5,928 14,604 Amortization expense — — — 5,881 5,881 Segment operating income (loss) $ 20,487 $ 21,192 $ (278 ) $ (48,583 ) $ (7,182 ) Other: Transaction and transition expenses 1,952 Operating loss (9,134 ) Interest expense, net 19,753 Other expense, net 3,902 Loss before income taxes $ (32,789 ) Three months ended September 24, 2017 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate 1 Total Net sales from external customers $ 70,946 $ 55,918 $ 43,639 $ — $ 170,503 Depreciation expense 3,871 2,372 3,298 5,459 15,000 Amortization expense — — — 7,178 7,178 Segment operating income (loss) $ 13,506 $ 16,575 $ (1,563 ) $ (43,716 ) $ (15,198 ) Other: Transaction and transition expenses 3,311 Operating loss (18,509 ) Interest expense, net 18,978 Other expense, net 5,457 Loss before income taxes $ (42,944 ) Selected financial information related to our segments is presented below for the nine months ended September 30, 2018 and September 24, 2017 (in thousands): Nine months ended September 30, 2018 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate 1 Total Net sales from external customers $ 235,595 $ 206,338 $ 156,110 $ — $ 598,043 Depreciation expense 7,729 8,350 9,604 17,303 42,986 Amortization expense — — — 19,031 19,031 Segment operating income (loss) $ 62,211 $ 69,864 $ (1,526 ) $ (138,044 ) $ (7,495 ) Other: Transaction and transition expenses 4,187 Operating loss (11,682 ) Interest expense, net 60,243 Other expense, net 75,649 Loss before income taxes $ (147,574 ) Nine months ended September 24, 2017 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate 1 Total Net sales from external customers $ 220,259 $ 171,695 $ 135,433 $ — $ 527,387 Depreciation expense 10,080 7,321 8,539 16,184 42,124 Amortization expense — — — 21,574 21,574 Segment operating income (loss) $ 51,988 $ 52,942 $ 1,641 $ (133,987 ) $ (27,416 ) Other: Transaction and transition expenses 9,484 Operating loss (36,900 ) Interest expense, net 55,512 Other expense, net 6,875 Loss before income taxes $ (99,287 ) 1 The Corporate category primarily reflects general and administrative expenses not specifically associated with the U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics segments. These non-allocated corporate expenses relate to global administrative expenses that support all segments, including salaries and benefits of certain executive officers and expenses such as: information technology administration and support; corporate headquarters; legal, compliance, and corporate finance functions; insurance; and all share-based compensation. Our principal geographic regions consist of the United States, EMEAC (which includes Europe, the Middle East, Africa, and Canada), and Other (which principally represents Asia, Australia, and Latin America). Net sales attributed to each geographic region are based on the location in which the products were sold. Net sales by geographic region by product line are as follows (in thousands): Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 United States Lower extremities $ 57,602 $ 51,417 $ 173,889 $ 161,228 Upper extremities 65,334 54,788 203,163 168,280 Biologics 20,654 18,640 59,053 56,547 Sports med & other 1,975 2,019 5,828 5,899 Total United States $ 145,565 $ 126,864 $ 441,933 $ 391,954 EMEAC Lower extremities $ 9,527 $ 9,022 $ 33,761 $ 30,379 Upper extremities 18,985 15,779 64,935 51,193 Biologics 1,828 1,727 6,244 6,159 Sports med & other 2,591 2,968 8,182 10,001 Total EMEAC $ 32,931 $ 29,496 $ 113,122 $ 97,732 Other Lower extremities $ 3,974 $ 4,941 $ 10,747 $ 11,993 Upper extremities 6,696 5,418 19,477 15,413 Biologics 4,721 3,466 12,144 9,333 Sports med & other 219 318 620 962 Total other $ 15,610 $ 14,143 $ 42,988 $ 37,701 Total net sales $ 194,106 $ 170,503 $ 598,043 $ 527,387 Assets in the U.S. Upper Extremities, U.S. Lower Extremities & Biologics, and International Extremities & Biologics segments are those assets used exclusively in the operations of each business segment or allocated when used jointly. Assets in the Corporate category are principally cash and cash equivalents, derivative assets, property, plant and equipment associated with our corporate headquarters, assets associated with discontinued operations, product liability insurance receivables, and assets associated with income taxes. Total assets by business segment as of September 30, 2018 and December 31, 2017 are as follows (in thousands): September 30, 2018 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate Total Total assets $ 524,265 $ 922,120 $ 249,051 $ 1,143,859 $ 2,839,295 December 31, 2017 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate Total Total assets $ 490,528 $ 929,930 $ 301,985 $ 406,281 $ 2,128,724

Subsequent Event Subsequent Eve

Subsequent Event Subsequent Event (Notes)	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Event During the third quarter of 2018, on August 24, 2018, we entered into a definitive agreement to acquire 100% of the outstanding equity on a fully diluted basis of Cartiva, Inc., an orthopaedic medical device company focused on treatment of osteoarthritis of the great toe, for a total price of $435 million in cash, subject to certain adjustments as set forth in the agreement. On October 10, 2018, we completed the acquisition. We funded the acquisition with the proceeds from a registered underwritten public offering of 18,248,932 ordinary shares which had net proceeds of $423.0 million . See Note 12 for additional details related to the public offering. This acquisition adds a differentiated pre-market approval (PMA) approved technology for a high-volume foot and ankle procedure and further accelerates growth opportunities in our global extremities business. The purchase price for this acquisition will be allocated to the identifiable assets acquired and liabilities assumed based on estimates of their relative fair values at October 10, 2018, the date of the acquisition, with the excess purchase price recorded as goodwill. Because the initial accounting for the business combination is incomplete at this time, we are unable to provide the purchase price allocation for this transaction.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation. The unaudited condensed consolidated interim financial statements of Wright Medical Group N.V. have been prepared in accordance with U.S. generally accepted accounting principles (US GAAP) for interim financial statements and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to these rules and regulations. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 , as filed with the SEC on February 27, 2018 . In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary for a fair presentation of our interim financial results. All such adjustments are of a normal and recurring nature. The results of operations for any interim period are not indicative of results for the full fiscal year. The accompanying unaudited condensed consolidated interim financial statements include our accounts and those of our controlled subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the dates of the financial statements and the amounts of revenues and expenses during the reporting periods. Actual amounts realized or paid could differ from those estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition. Our revenues are primarily generated through two types of customers, hospitals and surgery centers and stocking distributors, with the majority of our revenue derived from sales to hospitals and surgery centers. Our products are sold through a network of employee and independent sales representatives in the United States and by a combination of employee sales representatives, independent sales representatives, and stocking distributors outside the United States. We record revenues from sales to hospitals and surgery centers upon transfer of control of promised products in an amount that reflects the consideration we expect to receive in exchange for those products, which is generally when the product is surgically implanted in a patient. We record revenues from sales to our stocking distributors at a point in time upon transfer of control of promised products to the distributor. Our stocking distributors, who sell the products to their customers, take control of the products and assume all risks of ownership upon transfer. Our stocking distributors are obligated to pay us within specified terms regardless of when, if ever, they sell the products. In general, our stocking distributors do not have any rights of return or exchange; however, in limited situations, we have repurchase agreements with certain stocking distributors. Those certain agreements require us to repurchase a specified percentage of the inventory purchased by the distributor within a specified period of time prior to the expiration of the contract. During those specified periods, we defer the applicable percentage of the sales. An insignificant amount of sales related to these types of agreements was deferred and not yet recognized as revenue as of September 30, 2018 and December 31, 2017. We must make estimates of potential future product returns related to current period product sales. We base our estimate for sales returns on historical sales and product return information, including historical experience and trend information. Our reserve for sales returns has historically been immaterial. We incur shipping and handling costs associated with the shipment of goods to customers, independent distributors, and our subsidiaries. Amounts billed to customers for shipping and handling of products are included in net sales. Costs incurred related to shipping and handling of products to customers are included in selling, general and administrative expenses. We also record depreciation on surgical instruments used by our hospital and surgery center customers within selling, general and administrative expense as these costs are considered to be similar to shipping and handling costs, necessary to deliver the implant products to the end customer.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations. On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France SAS (Tornier France) and certain other entities related to us and Corin Orthopaedics Holdings Limited (Corin) entered into a business sale agreement and simultaneously completed and closed the sale of our former Large Joints business. Pursuant to the terms of the agreement, we sold substantially all of our assets related to our Large Joints business to Corin for approximately €29.7 million in cash, less approximately €11.1 million for net working capital adjustments. Upon closing, the parties also executed a transitional services agreement and supply agreement, among other ancillary agreements required to implement the transaction. These agreements were on arm’s length terms and were not material to our consolidated financial statements. On January 9, 2014, pursuant to an Asset Purchase Agreement, dated as of June 18, 2013 (the MicroPort Agreement), by and among us and MicroPort Scientific Corporation (MicroPort), we completed the divesture and sale of our business operations operating under our prior OrthoRecon operating segment to MicroPort. All historical operating results for the Large Joints and OrthoRecon businesses are reflected within discontinued operations in the condensed consolidated financial statements. See Note 4 for further discussion of discontinued operations. Other than Note 4 , unless otherwise stated, all discussion of assets and liabilities in these Notes to the condensed consolidated financial statements reflects the assets and liabilities held and used in our continuing operations, and all discussion of revenues and expenses reflects those associated with our continuing operations.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, and has subsequently issued several supplemental and/or clarifying ASUs (collectively ASC 606). Accounting Standards Codification (ASC) 606 prescribes a single common revenue standard that replaces most existing US GAAP revenue recognition guidance. ASC 606 outlines a five-step model, under which we will recognize revenue as performance obligations within a customer contract are satisfied. ASC 606 is intended to provide more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. We adopted ASC 606 during the quarter ended April 1, 2018. Revenue is recognized at a point in time, generally upon surgical implantation or shipment of products to distributors. Therefore, adoption of ASC 606 did not have a material effect on our consolidated financial statements except for the additional disclosures included within Note 14 . On February 25, 2016, the FASB issued ASU 2016-02, Leases, and has subsequently issued ASU 2018-10 and ASU 2018-11 which clarifies this guidance (collectively ASC 842). ASC 842 introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in FASB ASC 606, the FASB’s new revenue recognition standard (e.g., those related to evaluating when profit can be recognized). Furthermore, ASC 842 addresses other concerns related to the current leases model. ASC 842 will be effective for us beginning in fiscal year 2019. We have evaluated the practical expedients and plan to adopt the hindsight practical expedient, the practical expedient for short-term leases, the practical expedient package which primarily limits the need for reassessing lease classification on existing leases, and to issue our financial statements showing comparative lease disclosures under current GAAP. We do not anticipate adoption of these updates will have a material impact on net earnings or cash flows and continue to assess the impact on our consolidated balance sheets. On January 26, 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of step 2 of the goodwill impairment test. Under the new guidance, if a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The guidance in the ASU is effective for our interim and annual goodwill impairment tests beginning in 2020 with early adoption permitted. We are in the initial phases of our adoption plans; and, accordingly, we are unable to estimate any effect this may have on our consolidated financial statements.
Fair Value Measurement, Policy [Policy Text Block]	We account for derivatives in accordance with FASB ASC 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivatives' fair value shall be recognized currently in earnings unless specific hedge accounting criteria are met. FASB ASC Section 820, Fair Value Measurement requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Financial instruments with unadjusted, quoted prices listed on active market exchanges. Level 2: Financial instruments determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.
Earnings Per Share, Policy [Policy Text Block]	FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings per share is calculated based on the weighted-average number of ordinary shares outstanding during the period. Diluted earnings per share is calculated to include any dilutive effect of our ordinary share equivalents. For the three and nine months ended September 30, 2018 and September 24, 2017 , our ordinary share equivalents consisted of stock options, restricted stock units, performance share units, and warrants. The dilutive effect of the stock options, restricted stock units, performance share units, and warrants is calculated using the treasury-stock method.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Preliminary Allocation of the Purchase Consideration to the Assets Acquired and Liabilities Assumed	The following presents the preliminary allocation of the purchase consideration to the assets acquired and liabilities assumed on December 14, 2017 (in thousands): Cash and cash equivalents $ 2,559 Accounts receivable 102 Other current assets 925 Property, plant and equipment 20 Intangible assets 10,865 Total assets acquired 14,471 Current liabilities (2,173 ) Long-term debt (886 ) Deferred income taxes (2,343 ) Total liabilities assumed (5,402 ) Net assets acquired $ 9,069 Goodwill 71,064 Total preliminary purchase consideration $ 80,133

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2018
OrthoRecon Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	The following table summarizes the results of discontinued operations for the OrthoRecon business (in thousands): Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 Net sales $ — $ — $ — $ — Selling, general and administrative 8,553 96,917 (15,309 ) 137,578 (Loss) income from discontinued operations before income taxes (8,553 ) (96,917 ) 15,309 (137,578 ) (Benefit) provision for income taxes (2,188 ) — 3,995 — Total (loss) income from discontinued operations, net of tax $ (6,365 ) $ (96,917 ) $ 11,314 $ (137,578 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials $ 10,517 $ 10,816 Work-in-process 36,029 28,581 Finished goods 132,948 128,747 $ 179,494 $ 168,144

Derivatives and Fair Value of_2

Derivatives and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Derivatives, Fair Value [Line Items]
Schedule of Derivative Assets at Fair Value [Table Text Block]	The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2023 Notes Hedges and 2023 Notes Conversion Derivative: Location on condensed consolidated balance sheet September 30, 2018 2023 Notes Hedges Other assets $ 150,853 2023 Notes Conversion Derivative Other liabilities $ 151,107
Derivative Instruments, Gain (Loss) [Table Text Block]	The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2023 Notes Hedges and 2023 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 30, 2018 2023 Notes Hedges $ 25,880 $ 9,575 2023 Notes Conversion Derivative (25,244 ) (26,482 ) Net gain (loss) on changes in fair value $ 636 $ (16,907 )
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	e following assumptions were used in the fair market valuations as of September 30, 2018 : 2020 Notes Conversion Derivative 2020 Notes 2021 Notes Conversion Derivative 2021 Notes Hedge 2023 Notes Conversion Derivative 2023 Notes Hedge Stock Price Volatility (1) 31.92% 31.92% 37.55% 37.55% 30.64% 30.64% Credit Spread for Wright (2) 2.62% N/A 3.13% N/A 2.55% N/A Credit Spread for Deutsche Bank AG (3) N/A 1.27% N/A N/A N/A N/A Credit Spread for Wells Fargo Securities, LLC (3) N/A 0.15% N/A N/A N/A N/A Credit Spread for JPMorgan Chase Bank (3) N/A 0.17% N/A 0.27% N/A 0.4% Credit Spread for Bank of America (3) N/A N/A N/A 0.28% N/A 0.46% (1) Volatility selected based on historical and implied volatility of ordinary shares of Wright Medical Group N.V. (2) Credit spread implied from traded price. (3) Credit spread of each bank is estimated using CDS curves. Source: Bloomberg. D
Fair Value Financial Instruments [Table Text Block]	e following tables summarize the valuation of our financial instruments (in thousands): Total Quoted prices in active markets (Level 1) Prices with other observable inputs (Level 2) Prices with unobservable inputs (Level 3) At September 30, 2018 Assets Cash and cash equivalents $ 694,903 $ 694,903 $ — $ — 2020 Notes Hedges 27,327 — — 27,327 2021 Notes Hedges 222,919 — — 222,919 2023 Notes Hedges 150,853 — — 150,853 Total $ 1,096,002 $ 694,903 $ — $ 401,099 Liabilities 2020 Notes Conversion Derivative $ 26,757 $ — $ — $ 26,757 2021 Notes Conversion Derivative 221,356 — — 221,356 2023 Notes Conversion Derivative 151,107 — — 151,107 Contingent consideration 18,765 — — 18,765 Contingent consideration (CVRs) 39,241 39,241 — — Total $ 457,226 $ 39,241 $ — $ 417,985 Total Quoted prices Prices with Prices with At December 31, 2017 Assets Cash and cash equivalents $ 167,740 $ 167,740 $ — $ — 2020 Notes Hedges 45,033 — — 45,033 2021 Notes Hedges 127,063 — — 127,063 Total $ 339,836 $ 167,740 $ — $ 172,096 Liabilities 2020 Notes Conversion Derivative $ 44,132 $ — $ — $ 44,132 2021 Notes Conversion Derivative 126,148 — — 126,148 Contingent consideration 19,188 — — 19,188 Contingent consideration (CVRs) 42,325 42,325 — — Total $ 231,793 $ 42,325 $ — $ 189,468 The following is a roll forward of our assets and liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) (in thousands): Balance at December 31, 2017 Additions Transfers into Level 3 Gain/(loss) included in earnings Settlements Currency Balance at September 30, 2018 2020 Notes Hedges $ 45,033 — — 16,847 (34,553 ) — $ 27,327 2020 Notes Conversion Derivative $ (44,132 ) — — (38,268 ) 55,643 — $ (26,757 ) 2020 Warrants Derivative $ — (27,308 ) — 3,336 23,972 — $ — 2021 Notes Hedges $ 127,063 — — 95,856 — — $ 222,919 2021 Notes Conversion Derivative $ (126,148 ) — — (95,208 ) — — $ (221,356 ) 2023 Notes Hedges $ — 141,278 — 9,575 — — $ 150,853 2023 Notes Conversion Derivative $ — (124,625 ) — (26,482 ) — — $ (151,107 ) Contingent consideration $ (19,188 ) — — (1,280 ) 919 784 $ (18,765 )
2021 Derivatives [Member]
Derivatives, Fair Value [Line Items]
Schedule of Derivative Assets at Fair Value [Table Text Block]	The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2021 Notes Hedges and 2021 Notes Conversion Derivative: September 30, 2018 December 31, 2017 Location on condensed consolidated balance sheet Amount Location on condensed consolidated balance sheet Amount 2021 Notes Hedges Other current assets $ 222,919 Other assets $ 127,063 2021 Notes Conversion Derivative Accrued expenses and other current liabilities $ 221,356 Other liabilities $ 126,148
Derivative Instruments, Gain (Loss) [Table Text Block]	The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2021 Notes Hedges and 2021 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 2021 Notes Hedges $ 46,591 $ (9,074 ) $ 95,856 $ 18,723 2021 Notes Conversion Derivative (45,715 ) 9,321 (95,208 ) (16,269 ) Net gain on changes in fair value $ 876 $ 247 $ 648 $ 2,454
2017 Derivatives [Member]
Derivatives, Fair Value [Line Items]
Derivative Instruments, Gain (Loss) [Table Text Block]	e following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2017 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 2017 Notes Conversion Derivative $ — $ 15 $ — $ (51 ) Net gain (loss) on changes in fair value $ — $ 15 $ — $ (51 ) T
2020 Derivatives [Member]
Derivatives, Fair Value [Line Items]
Schedule of Derivative Assets at Fair Value [Table Text Block]	The following table summarizes the fair value and the presentation in our condensed consolidated balance sheets (in thousands) of the 2020 Notes Hedges and 2020 Notes Conversion Derivative: September 30, 2018 December 31, 2017 Location on condensed consolidated balance sheet Amount Location on condensed consolidated balance sheet Amount 2020 Notes Hedges Other current assets $ 27,327 Other assets $ 45,033 2020 Notes Conversion Derivative Accrued expenses and other current liabilities $ 26,757 Other liabilities $ 44,132
Derivative Instruments, Gain (Loss) [Table Text Block]	e following table summarizes the net (loss) gain on changes in fair value (in thousands) related to the 2020 Notes Hedges, 2020 Warrants Derivative and 2020 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 2020 Notes Hedges $ 3,317 $ (10,340 ) $ 16,847 $ (3,538 ) 2020 Warrants Derivative 3,586 — 3,336 — 2020 Notes Conversion Derivative (8,186 ) 10,292 (38,268 ) 5,298 Net (loss) gain on changes in fair value $ (1,283 ) $ (48 ) $ (18,085 ) $ 1,760

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment, Net [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment, net consists of the following (in thousands): September 30, 2018 December 31, 2017 Property, plant and equipment, at cost $ 519,226 $ 448,921 Less: Accumulated depreciation (298,051 ) (236,542 ) $ 221,175 $ 212,379

Goodwill and Intangibles (Table

Goodwill and Intangibles (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill Table	Changes in the carrying amount of goodwill occurring during the nine months ended September 30, 2018 are as follows (in thousands): U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Total Goodwill at December 31, 2017 $ 218,525 $ 630,650 $ 84,487 $ 933,662 Goodwill adjustment associated with IMASCAP acquisition — (917 ) — (917 ) Foreign currency translation — (1,111 ) (10,258 ) (11,369 ) Goodwill at September 30, 2018 $ 218,525 $ 628,622 $ 74,229 $ 921,376
Components of Identifiable Assets Table	The components of our identifiable intangible assets, net, are as follows (in thousands): September 30, 2018 December 31, 2017 Cost Accumulated amortization Cost Accumulated amortization Indefinite life intangibles: In-process research and development (IPRD) technology $ 5,178 $ 6,422 Finite life intangibles: Distribution channels 900 $ 835 900 $ 640 Completed technology 147,619 50,901 149,645 40,810 Licenses 6,547 1,706 5,268 1,530 Customer relationships 127,807 28,414 129,693 23,268 Trademarks 14,135 11,536 14,368 10,487 Non-compete agreements 3,111 2,315 3,964 2,603 Other 525 525 569 490 Total finite life intangibles 300,644 $ 96,232 304,407 $ 79,828 Total intangibles 305,822 310,829 Less: Accumulated amortization (96,232 ) (79,828 ) Intangible assets, net $ 209,590 $ 231,001

Long-Term Debt and Capital Le_2

Long-Term Debt and Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2018
Long-term Debt and Capital Lease Obligations [Abstract]
Schedule of Long-term Debt Instruments	Debt and capital lease obligations consist of the following (in thousands): September 30, 2018 December 31, 2017 Capital lease obligations $ 22,875 $ 20,401 2023 Notes 542,575 — 2021 Notes 1 315,793 300,051 2020 Notes 1 170,798 513,014 Term Loan Facility 18,903 — Asset-based line of credit 21,549 53,645 Other debt 9,019 8,003 1,101,512 895,114 Less: Current portion 1 (514,930 ) (58,906 ) $ 586,582 $ 836,208
Convertible Debt [Table Text Block]	The components of the 2023 Notes were as follows (in thousands): September 30, 2018 Principal amount of 2023 Notes $ 675,000 Unamortized debt discount (119,519 ) Unamortized debt issuance costs (12,906 ) Net carrying amount of 2023 Notes $ 542,575
Components of 2021 Convertible Debt [Table Text Block]	The components of the 2021 Notes were as follows (in thousands): September 30, 2018 December 31, 2017 Principal amount of 2021 Notes $ 395,000 $ 395,000 Unamortized debt discount (74,552 ) (89,332 ) Unamortized debt issuance costs (4,655 ) (5,617 ) Net carrying amount of 2021 Notes $ 315,793 $ 300,051
Components of 2020 Convertible Debt [Table Text Block]	The components of the 2020 Notes were as follows (in thousands): September 30, 2018 December 31, 2017 Principal amount of 2020 Notes $ 186,589 $ 587,500 Unamortized debt discount (14,081 ) (66,418 ) Unamortized debt issuance costs (1,710 ) (8,068 ) Net carrying amount of 2020 Notes $ 170,798 $ 513,014

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2018
Accumulated Other Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in AOCI for the nine months ended September 30, 2018 and September 24, 2017 were as follows (in thousands): Nine months ended September 30, 2018 Currency translation adjustment Balance at December 31, 2017 $ 22,290 Other comprehensive loss (19,642 ) Balance at September 30, 2018 $ 2,648 Nine months ended September 24, 2017 Currency translation adjustment Balance at December 25, 2016 $ (19,461 ) Other comprehensive income 44,362 Balance at September 24, 2017 $ 24,901

Changes in Stockholders' Equi_2

Changes in Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Changes in Stockholders' Equity [Abstract]
Schedule of Stockholders Equity [Table Text Block]	The following table provides an analysis of changes in each balance sheet caption of shareholders’ equity for the nine months ended September 30, 2018 and September 24, 2017 (in thousands, except share data): Nine months ended September 30, 2018 Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income (loss) Total shareholders' equity Number of shares Amount Balance at December 31, 2017 105,807,424 $ 3,896 $ 1,971,347 $ (1,408,837 ) $ 22,290 $ 588,696 2018 Activity: Net loss — — — (135,737 ) — (135,737 ) Foreign currency translation — — — — (19,642 ) (19,642 ) Issuances of ordinary shares 556,827 20 10,955 — — 10,975 Shares issued for public offering ( Note 12 ) 18,248,932 641 422,371 — — 423,012 Vesting of restricted stock units 452,057 16 (16 ) — — — Share-based compensation — — 18,238 — — 18,238 Issuance of stock warrants, net of repurchases and equity issuance costs — — 72,956 — — 72,956 Balance at September 30, 2018 125,065,240 $ 4,573 $ 2,495,851 $ (1,544,574 ) $ 2,648 $ 958,498 Nine months ended September 24, 2017 Ordinary shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive (loss) income Total shareholders' equity Number of shares Amount Balance at December 25, 2016 103,400,995 $ 3,815 $ 1,908,749 $ (1,206,239 ) $ (19,461 ) $ 686,864 2017 Activity: Net loss — — — (231,731 ) — (231,731 ) Foreign currency translation — — — — 44,362 44,362 Issuances of ordinary shares 1,217,088 40 24,788 — — 24,828 Vesting of restricted stock units 393,595 13 (13 ) — — — Share-based compensation — — 14,193 — — 14,193 Balance at September 24, 2017 105,011,678 $ 3,868 $ 1,947,717 $ (1,437,970 ) $ 24,901 $ 538,516

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Weighted Average Number of Shares Outstanding for Basic and Diluted Earnings Per Share	The weighted-average number of ordinary shares outstanding for basic and diluted earnings per share purposes is as follows (in thousands): Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 Weighted-average number of ordinary shares outstanding-basic and diluted 113,043 104,836 108,348 104,292

Segment Data (Tables)

Segment Data (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Data [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Selected financial information related to our segments is presented below for the three months ended September 30, 2018 and September 24, 2017 (in thousands): Three months ended September 30, 2018 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate 1 Total Net sales from external customers $ 79,296 $ 66,269 $ 48,541 $ — $ 194,106 Depreciation expense 2,474 2,836 3,366 5,928 14,604 Amortization expense — — — 5,881 5,881 Segment operating income (loss) $ 20,487 $ 21,192 $ (278 ) $ (48,583 ) $ (7,182 ) Other: Transaction and transition expenses 1,952 Operating loss (9,134 ) Interest expense, net 19,753 Other expense, net 3,902 Loss before income taxes $ (32,789 ) Three months ended September 24, 2017 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate 1 Total Net sales from external customers $ 70,946 $ 55,918 $ 43,639 $ — $ 170,503 Depreciation expense 3,871 2,372 3,298 5,459 15,000 Amortization expense — — — 7,178 7,178 Segment operating income (loss) $ 13,506 $ 16,575 $ (1,563 ) $ (43,716 ) $ (15,198 ) Other: Transaction and transition expenses 3,311 Operating loss (18,509 ) Interest expense, net 18,978 Other expense, net 5,457 Loss before income taxes $ (42,944 )
Net Sales and Operating Income by Product Line and Information by Geographic Region	Net sales by geographic region by product line are as follows (in thousands): Three months ended Nine months ended September 30, 2018 September 24, 2017 September 30, 2018 September 24, 2017 United States Lower extremities $ 57,602 $ 51,417 $ 173,889 $ 161,228 Upper extremities 65,334 54,788 203,163 168,280 Biologics 20,654 18,640 59,053 56,547 Sports med & other 1,975 2,019 5,828 5,899 Total United States $ 145,565 $ 126,864 $ 441,933 $ 391,954 EMEAC Lower extremities $ 9,527 $ 9,022 $ 33,761 $ 30,379 Upper extremities 18,985 15,779 64,935 51,193 Biologics 1,828 1,727 6,244 6,159 Sports med & other 2,591 2,968 8,182 10,001 Total EMEAC $ 32,931 $ 29,496 $ 113,122 $ 97,732 Other Lower extremities $ 3,974 $ 4,941 $ 10,747 $ 11,993 Upper extremities 6,696 5,418 19,477 15,413 Biologics 4,721 3,466 12,144 9,333 Sports med & other 219 318 620 962 Total other $ 15,610 $ 14,143 $ 42,988 $ 37,701 Total net sales $ 194,106 $ 170,503 $ 598,043 $ 527,387
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Total assets by business segment as of September 30, 2018 and December 31, 2017 are as follows (in thousands): September 30, 2018 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate Total Total assets $ 524,265 $ 922,120 $ 249,051 $ 1,143,859 $ 2,839,295 December 31, 2017 U.S. Lower Extremities & Biologics U.S. Upper Extremities International Extremities & Biologics Corporate Total Total assets $ 490,528 $ 929,930 $ 301,985 $ 406,281 $ 2,128,724

Organization and Description _2

Organization and Description of Business (Details)	9 Months Ended
	Sep. 30, 2018segment
Business Acquisition [Line Items]
Number of Operating Segments	3
Number of countries in which entity operates	50

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Thousands, € in Millions	Dec. 14, 2017USD ($)shares	Sep. 30, 2018USD ($)	Dec. 14, 2017EUR (€)
Business Acquisition [Line Items]
Ownership interest acquired	100.00%		100.00%
Goodwill, Purchase Accounting Adjustments		$ (917)
IMASCAP SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs	$ 62,300		€ 52.9
Contingent consideration	$ 17,800		15.1
Number of shares acquired | shares	661,753
Intangible assets acquired	$ 10,865
IMASCAP SAS [Member] | Technology-Based Intangible Assets [Member]
Business Acquisition [Line Items]
Intangible assets acquired	$ 5,600
Useful life of intangible assets	6 years
IMASCAP SAS [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Intangible assets acquired	$ 5,300
IMASCAP SAS [Member] | Cash [Member]
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs	46,700		39.7
IMASCAP SAS [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs	$ 15,600		€ 13.2
Upper Extremities [Member] | UNITED STATES
Business Acquisition [Line Items]
Goodwill, Purchase Accounting Adjustments		$ (917)

Acquisitions - Preliminary Allo

Acquisitions - Preliminary Allocation of the Purchase Consideration to the Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 14, 2017
Business Acquisition [Line Items]
Goodwill	$ 921,376	$ 933,662
Goodwill, Purchase Accounting Adjustments	$ (917)
IMASCAP SAS [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			$ 2,559
Accounts receivable			102
Other current assets			925
Property, plant and equipment			20
Intangible assets			10,865
Total assets acquired			14,471
Current liabilities			(2,173)
Long-term debt			(886)
Deferred income taxes			(2,343)
Total liabilities assumed			(5,402)
Net assets acquired			9,069
Goodwill			71,064
Total preliminary purchase consideration			$ 80,133

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	May 08, 2018	Oct. 21, 2016	Sep. 01, 2015	Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent				$ (6,696)	$ (97,748)	$ 10,620	$ (139,942)
Net (loss) income from discontinued operations per share-basic and diluted (Note 12):				$ (0.06)	$ (0.93)	$ 0.10	$ (1.34)
Weighted-average number of ordinary shares outstanding-basic and diluted:				113,043	104,836	108,348	104,292
Large Joints Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price Discontinued Operations		$ 29,700
Net Working Capital Not Transferred in Disposal		$ 11,100
Cash Provided by (Used in) Operating Activities, Discontinued Operations						$ 2,700	$ 3,500
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Per Basic Share				$ 300,000	$ 900,000	$ 700,000	$ 2,400,000
OrthoRecon Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent				$ (6,365)	$ (96,917)	$ 11,314	$ (137,578)
Cash Provided by (Used in) Operating Activities, Discontinued Operations						46,800	142,700
Disposal Group, Including Discontinued Operation, Revenue				0	0	0	0
Disposal Group, Including Discontinued Operation, General and Administrative Expense				8,553	96,917	(15,309)	137,578
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax				(8,553)	(96,917)	15,309	(137,578)
Discontinued Operation, Tax Effect of Discontinued Operation				$ (2,188)	$ 0	$ 3,995	$ 0
PROFEMUR Titanium Modular Neck Product [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss Contingency, Receivable, Period Increase (Decrease)			$ 25,000
Insurance Carrier [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Legal Settlements	$ 30,750
Insurance Policy Limit	25,000
Insurance Policy, Costs And Interest Received	$ 5,750

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 10,517	$ 10,816
Work-in-process	36,029	28,581
Finished goods	132,948	128,747
Total Inventory	$ 179,494	$ 168,144

Derivatives and Fair Value of_3

Derivatives and Fair Value of Financial Instruments (Details) $ / shares in Units, $ in Thousands	May 20, 2016USD ($)counterparty	May 12, 2016	Sep. 01, 2015USD ($)$ / shares	Feb. 13, 2015USD ($)	Aug. 31, 2012	Aug. 31, 2008	Mar. 01, 2013$ / shares	Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)	Sep. 30, 2018USD ($)$ / shares	Sep. 24, 2017USD ($)	Jun. 28, 2018counterparty	Dec. 31, 2017USD ($)
Schedule of Marketable Securities [Line Items]
Cash and Cash Equivalents, at Carrying Value								$ 694,903		$ 694,903			$ 167,740
ThresholdForConversionAsPercentOfConversionPrice				130.00%		130.00%				130.00%
Cash Payment, Contingent Consideration										$ 42,000
Cash and Cash Equivalents, Fair Value Disclosure								694,903		694,903			167,740
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability										(3,084)	$ 6,721
Non-cash adjustment to derivative fair values										$ 34,343	(4,163)
Debt Instrument, Convertible, Minimum Consecutive Period					5 days	20 days				5 days
Debt Instrument, Convertible, Trading Period				30 days		30 days				30 days
2021 Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(45,715)	$ 9,321	$ (95,208)	(16,269)
2021 Notes Hedges [Member]
Schedule of Marketable Securities [Line Items]
Derivative, Gain (Loss) on Derivative, Net								46,591	(9,074)	95,856	18,723
2017 Notes Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Derivative, Gain (Loss) on Derivative, Net								0	15	0	(51)
2020 Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(8,186)	10,292	(38,268)	5,298
Fair Value, Measurements, Recurring [Member]
Schedule of Marketable Securities [Line Items]
Total Assets								1,096,002		1,096,002			339,836
Total Liabilities								457,226		457,226			231,793
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Schedule of Marketable Securities [Line Items]
Total Assets								694,903		694,903			167,740
Total Liabilities								39,241		39,241			42,325
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Schedule of Marketable Securities [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure								0		0			0
Total Assets								0		0			0
Total Liabilities								0		0			0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure								0		0			0
Total Assets								401,099		401,099			172,096
Total Liabilities								417,985		417,985			189,468
BMTI Payment of Conditional Value Rights [Member]
Schedule of Marketable Securities [Line Items]
Price per share of contingent consideration | $ / shares			$ 3.50				$ 6.50
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			$ 98,100
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								18,765		18,765			19,188
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								0		0			0
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								0		0			0
Contingent Consideration [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								18,765		18,765			19,188
Contingent Value Rights [Member] | Fair Value, Measurements, Recurring [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								39,241		39,241			42,325
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset								3,400	4,500	3,100	6,700
Contingent Value Rights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								39,241		39,241			42,325
Contingent Value Rights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								0		0			0
Contingent Value Rights [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								0		$ 0			0
AUGMENT Bone Graft Payment of Conditional Value Rights, Condition One [Member]
Schedule of Marketable Securities [Line Items]
Price per share of contingent consideration | $ / shares										$ 1.50
AUGMENT Bone Graft Payment of Conditional Value Rights, Condition Two [Member]
Schedule of Marketable Securities [Line Items]
Price per share of contingent consideration | $ / shares										$ 1.50
AUGMENT Bone Graft Payment of Conditional Value Rights, Condition Two [Member] | Fair Value, Measurements, Recurring [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value								70,000		$ 70,000
2023 Note Hedges [Member]
Schedule of Marketable Securities [Line Items]
Number of Counterparties | counterparty												2
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value								150,853		150,853			0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings										9,575
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales										141,278
Derivative Asset, Fair Value, Gross Asset								150,853		150,853
2023 Note Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Asset, Fair Value, Gross Asset								150,853		150,853
2020 Settled Hedges [Member]
Schedule of Marketable Securities [Line Items]
Derivative Asset, Fair Value, Gross Asset								27,327		27,327
2020 Settled Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Asset, Fair Value, Gross Asset								27,327		27,327
2021 Notes Hedges [Member]
Schedule of Marketable Securities [Line Items]
Number of Counterparties | counterparty	2
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value								222,919		222,919			127,063
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings										95,856
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales										0
Derivative Asset, Fair Value, Gross Asset								222,919		222,919			127,063
2021 Notes Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Asset, Fair Value, Gross Asset								222,919		222,919			127,063
2020 Notes Hedges [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value								27,327		27,327			45,033
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings										16,847
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements										(34,553)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales										0
Derivative Asset, Fair Value, Gross Asset													45,033
2020 Notes Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Asset, Fair Value, Gross Asset													45,033
2020 Warrants Derivative [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements										23,972
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value								0		0			0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases										(27,308)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings										3,336
2021 Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value								221,356		221,356			126,148
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings										(95,208)
Derivative Liability, Fair Value, Gross Liability								221,356		221,356			126,148
2021 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Liability, Fair Value, Gross Liability								221,356		221,356			126,148
2020 Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	$ 400									55,643
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value								26,757		26,757			44,132
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases										0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings										(38,268)
2020 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Liability, Fair Value, Gross Liability								26,757		26,757			44,132
2020 Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member]
Schedule of Marketable Securities [Line Items]
Derivative Liability, Fair Value, Gross Liability								26,757		26,757			44,132
Contingent Consideration [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										784
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements										919
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value								18,765		18,765			19,188
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings										(1,280)
2017 Notes Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements				$ 49,000
2023 Conversion Derivative [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Currency										0
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value								151,107		151,107			0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases										(124,625)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings										(26,482)
2023 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member]
Schedule of Marketable Securities [Line Items]
Derivative Liability, Fair Value, Gross Liability								151,107		151,107
2023 Conversion Derivative [Member] | Fair Value, Measurements, Recurring [Member]
Schedule of Marketable Securities [Line Items]
Derivative Liability, Fair Value, Gross Liability								151,107		151,107
SSP - Distribution Business [Member]
Schedule of Marketable Securities [Line Items]
Contingent Consideration Fair Value													900
SSP - Distribution Business [Member] | Contingent Consideration [Member]
Schedule of Marketable Securities [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases										0
2021 Convertible Debt [Member]
Schedule of Marketable Securities [Line Items]
Number of Counterparties | counterparty	2
Long-term Debt, Gross								395,000		395,000			$ 395,000
Debt Instrument, Convertible, Trading Period		100 days
2021 Change in Derivative fair Value [Member]
Schedule of Marketable Securities [Line Items]
Non-cash adjustment to derivative fair values								$ 876	$ 247	$ 648	$ 2,454

Derivatives and Fair Value of_4

Derivatives and Fair Value of Financial Instruments Derivatives (Details)	Jul. 30, 2018USD ($)	Jun. 28, 2018USD ($)counterparty	Aug. 15, 2017USD ($)	May 20, 2016USD ($)counterparty	May 12, 2016	Sep. 01, 2015USD ($)$ / shares	Feb. 13, 2015USD ($)counterparty	Aug. 31, 2012USD ($)counterparty	Aug. 31, 2008	Mar. 01, 2013$ / shares	Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)	Sep. 30, 2018USD ($)$ / shares	Sep. 24, 2017USD ($)	Oct. 28, 2018USD ($)	Dec. 31, 2017USD ($)
Derivatives, Fair Value [Line Items]
ThresholdForConversionAsPercentOfConversionPrice							130.00%		130.00%				130.00%
Debt Instrument, Convertible, Minimum Consecutive Period								5 days	20 days				5 days
Debt Instrument, Convertible, Trading Period							30 days		30 days				30 days
Derivative Instruments, Gain (Loss) [Table Text Block]													The following table summarizes the net gain (loss) on changes in fair value (in thousands) related to the 2023 Notes Hedges and 2023 Notes Conversion Derivative: Three months ended Nine months ended September 30, 2018 September 30, 2018 2023 Notes Hedges $ 25,880 $ 9,575 2023 Notes Conversion Derivative (25,244 ) (26,482 ) Net gain (loss) on changes in fair value $ 636 $ (16,907 )
Cash and Cash Equivalents, at Carrying Value											$ 694,903,000		$ 694,903,000			$ 167,740,000
Cash Payment, Contingent Consideration													42,000,000
Non Cash Adjustment Derivative Fair Value													(34,343,000)	$ 4,163,000
Payments for Repurchase of Warrants													23,972,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability													(3,084,000)	6,721,000
Payment of notes hedge option													$ 34,553,000
2017 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Number of Counterparties | counterparty								3
Payments for (Proceeds from) Hedge, Financing Activities								$ 56,200,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements							$ 70,000,000
2023 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value Assumptions, Expected Volatility Rate													30.64%
Derivative, Gain (Loss) on Derivative, Net											(25,244,000)		$ (26,482,000)
2020 Warrants Derivative [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net											3,586,000	$ 0	3,336,000	0
2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net											3,317,000	(10,340,000)	$ 16,847,000	(3,538,000)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements				$ 3,900,000
2020 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value Assumptions, Expected Volatility Rate													31.92%
Debt Instrument, Unamortized Discount							$ 149,800,000
Derivative, Gain (Loss) on Derivative, Net											(8,186,000)	10,292,000	$ (38,268,000)	5,298,000
2021 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net											46,591,000	(9,074,000)	95,856,000	18,723,000
2017 Notes Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Debt Instrument, Unamortized Discount								$ 48,100,000
Derivative, Gain (Loss) on Derivative, Net											0	15,000	$ 0	(51,000)
2021 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value Assumptions, Expected Volatility Rate													37.55%
Derivative, Gain (Loss) on Derivative, Net											(45,715,000)	9,321,000	$ (95,208,000)	(16,269,000)
2023 Note Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net											25,880,000		9,575,000
2020 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Payment of notes hedge option		$ 27,300,000
2021 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Debt Instrument, Unamortized Discount				117,200,000
2020 convertibledebt [Member]
Derivatives, Fair Value [Line Items]
Stated percentage rate							2.00%
Debt Instrument, Unamortized Discount											14,081,000		14,081,000			66,418,000
Extinguishment of Debt, Amount				45,000,000
Repayments of Debt				44,600,000			$ 292,000,000
Payments for Repurchase of Warrants				3,300,000
Payment of notes hedge option				600,000
2017 Convertible Debt [Member]
Derivatives, Fair Value [Line Items]
Stated percentage rate								2.00%
Extinguishment of Debt, Amount				54,400,000
Repayments of Debt			$ 2,000,000	$ 56,300,000			240,000,000
Debt Instrument, Periodic Payment, Interest							2,400,000
Payments for Repurchase of Warrants							60,000,000
Payment of notes hedge option							$ 10,000,000
2021 Convertible Debt [Member]
Derivatives, Fair Value [Line Items]
Debt Instrument, Convertible, Trading Period					100 days
Long-term Debt, Gross											395,000,000		395,000,000			395,000,000
Stated percentage rate				2.25%
Debt Instrument, Unamortized Discount											74,552,000		74,552,000			89,332,000
Number of Counterparties | counterparty				2
2021 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Cost of Hedge				$ 99,800,000
2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Number of Counterparties | counterparty							3
Derivative, Cost of Hedge							$ 144,800,000
2017 Change in Derivative Fair Value [Member]
Derivatives, Fair Value [Line Items]
Non Cash Adjustment Derivative Fair Value											0	(15,000)	0	51,000
2020 Change in Derivative Fair Value [Member]
Derivatives, Fair Value [Line Items]
Non Cash Adjustment Derivative Fair Value											1,283,000	48,000	18,085,000	(1,760,000)
2021 Change in Derivative fair Value [Member]
Derivatives, Fair Value [Line Items]
Non Cash Adjustment Derivative Fair Value											(876,000)	(247,000)	$ (648,000)	(2,454,000)
Wright Medical Group, Inc. [Member] | 2023 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													2.55%
Wright Medical Group, Inc. [Member] | 2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Assumptions, Expected Volatility Rate													31.92%
Wright Medical Group, Inc. [Member] | 2020 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													2.62%
Wright Medical Group, Inc. [Member] | 2021 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Assumptions, Expected Volatility Rate													37.55%
Wright Medical Group, Inc. [Member] | 2021 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													3.13%
Wright Medical Group, Inc. [Member] | 2023 Note Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Assumptions, Expected Volatility Rate													30.64%
DEUTSCHE BANK SUPER X [Member] | 2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													1.27%
WELLS FARGO LIQUIDITY CROSS ATS [Member] | 2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													0.15%
JP Morgan Chase Bank [Member] | 2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													0.17%
JP Morgan Chase Bank [Member] | 2021 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													0.27%
JP Morgan Chase Bank [Member] | 2023 Note Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													0.40%
Bank of America [Member] | 2021 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													0.28%
Bank of America [Member] | 2023 Note Hedges [Member]
Derivatives, Fair Value [Line Items]
Fair Value Inputs, Entity Credit Risk													0.46%
BMTI Payment of Conditional Value Rights [Member]
Derivatives, Fair Value [Line Items]
Price per share of contingent consideration | $ / shares						$ 3.50				$ 6.50
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability						$ 98,100,000
AUGMENT Bone Graft Payment of Conditional Value Rights, Condition One [Member]
Derivatives, Fair Value [Line Items]
Price per share of contingent consideration | $ / shares													$ 1.50
AUGMENT Bone Graft Payment of Conditional Value Rights, Condition Two [Member]
Derivatives, Fair Value [Line Items]
Price per share of contingent consideration | $ / shares													$ 1.50
SSP - Distribution Business [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value																900,000
2020 Warrants Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements													$ 23,972,000
Payments For Warrants	$ 24,000,000
2021 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability											221,356,000		221,356,000			126,148,000
2021 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability											221,356,000		221,356,000			126,148,000
2020 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Proceeds From Derivatives Settled		$ 55,600,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements				400,000									55,643,000
2020 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability											26,757,000		26,757,000			44,132,000
2020 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Liability [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability											26,757,000		26,757,000			44,132,000
2017 Notes Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Repayments of Debt				$ 3,600,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements							49,000,000
2023 Note Hedges [Member]
Derivatives, Fair Value [Line Items]
Number of Counterparties | counterparty		2
Derivative Asset, Fair Value, Gross Asset											150,853,000		150,853,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements													0
Derivative, Cost of Hedge		$ 141,300,000
2023 Note Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset											150,853,000		150,853,000
2020 Settled Hedges [Member]
Derivatives, Fair Value [Line Items]
Proceeds From Derivatives Settled	$ 34,600,000
Derivative Asset, Fair Value, Gross Asset											27,327,000		27,327,000
2020 Settled Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset											27,327,000		27,327,000
2021 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Number of Counterparties | counterparty				2
Derivative Asset, Fair Value, Gross Asset											222,919,000		222,919,000			127,063,000
2021 Notes Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset											222,919,000		222,919,000			127,063,000
2020 Notes Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset																45,033,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements													(34,553,000)
2020 Notes Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset																45,033,000
2020 Notes Hedges [Member] | Fair Value, Inputs, Level 3 [Member] | Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset											27,327,000		27,327,000			45,033,000
2017 Convertible Debt [Member] | 2021 Convertible Debt [Member]
Derivatives, Fair Value [Line Items]
Extinguishment Of Debt, Amount Delivered Per Incremental Amount Exchanged				$ 1,035.40
2020 convertibledebt [Member] | 2021 Convertible Debt [Member]
Derivatives, Fair Value [Line Items]
Extinguishment Of Debt, Amount Delivered Per Incremental Amount Exchanged				990
Debt Exchange [Member] | 2017 Notes Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements			$ 200,000	1,900,000
Debt Repayment [Member] | 2017 Notes Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements				100,000
Reported Value Measurement [Member] | 2020 convertibledebt [Member]
Derivatives, Fair Value [Line Items]
Long-term Debt, Gross							$ 632,500,000				186,589,000		186,589,000			587,500,000
Reported Value Measurement [Member] | 2017 Convertible Debt [Member]
Derivatives, Fair Value [Line Items]
Long-term Debt, Gross								$ 300,000,000
Reported Value Measurement [Member] | 2021 Convertible Debt [Member]
Derivatives, Fair Value [Line Items]
Long-term Debt, Gross				$ 395,000,000
Fair Value, Measurements, Recurring [Member] | Contingent Consideration [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											18,765,000		18,765,000			19,188,000
Fair Value, Measurements, Recurring [Member] | Contingent Consideration [Member] | Fair Value, Inputs, Level 1 [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											0		0			0
Fair Value, Measurements, Recurring [Member] | Contingent Consideration [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											18,765,000		18,765,000			19,188,000
Fair Value, Measurements, Recurring [Member] | Contingent Value Rights [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											39,241,000		39,241,000			42,325,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset											3,400,000	$ 4,500,000	3,100,000	$ 6,700,000
Fair Value, Measurements, Recurring [Member] | Contingent Value Rights [Member] | Fair Value, Inputs, Level 1 [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											39,241,000		39,241,000			42,325,000
Fair Value, Measurements, Recurring [Member] | Contingent Value Rights [Member] | Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											0		0			0
Fair Value, Measurements, Recurring [Member] | AUGMENT Bone Graft Payment of Conditional Value Rights, Condition Two [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value											70,000,000		70,000,000
Fair Value, Measurements, Recurring [Member] | 2020 Conversion Derivative [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability											$ 26,757,000		$ 26,757,000			$ 44,132,000
Circumstance 1 [Domain]
Derivatives, Fair Value [Line Items]
Debt Instrument, Convertible, Minimum Consecutive Period													20 days
Subsequent Event [Member]
Derivatives, Fair Value [Line Items]
Cash Payment, Contingent Consideration															$ 42,000,000
Subsequent Event [Member] | Fair Value, Measurements, Recurring [Member] | AUGMENT Bone Graft Payment of Conditional Value Rights, Condition One [Member]
Derivatives, Fair Value [Line Items]
Contingent Consideration Fair Value															$ 40,000,000

Derivatives and Fair Value of_5

Derivatives and Fair Value of Financial Instruments - Additional Information (Details) $ / shares in Units, € in Millions, shares in Millions	Jun. 28, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)
Derivative [Line Items]
Non-cash adjustment to derivative fair values			$ 34,343,000	$ (4,163,000)
2023 Convertible Debt [Member]
Derivative [Line Items]
Principal Amount	$ 675,000,000	$ 675,000,000	675,000,000
Stated percentage rate	1.625%
Long-term Debt, Fair Value		715,800,000	715,800,000
Debt Conversion, Converted Instrument, Amount Delivered	$ 1,138.70
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | shares	20.2
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 40.86
2023 Note Hedges [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset		150,853,000	150,853,000
Derivative, Cost of Hedge	$ 141,300,000
2023 Note Hedges [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset		150,853,000	150,853,000
2023 Conversion Derivative [Member]
Derivative [Line Items]
Long-term Debt, Fair Value	$ 124,600,000
2023 Conversion Derivative [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability		151,107,000	151,107,000
2023 Note Hedges [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net		25,880,000	9,575,000
2023 Conversion Derivative [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net		(25,244,000)	(26,482,000)
2023 Change in Derivative fair Value [Member]
Derivative [Line Items]
Non-cash adjustment to derivative fair values		636,000	(16,907,000)
Technical Milestones And Sales Earnouts [Member] | IMASCAP SAS [Member]
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability					$ 18,600,000	€ 16.1
Technical Milestones [Member] | IMASCAP SAS [Member]
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability		12,400,000	$ 12,400,000		11,900,000
Fair Value Inputs, Discount Rate			6.00%
Sales Earnouts [Member] | IMASCAP SAS [Member]
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability		$ 6,300,000	$ 6,300,000		$ 5,900,000
Fair Value Inputs, Discount Rate			12.00%
Sales Earnouts [Member] | Surgical Specialties Australia Pty. Ltd [Member]
Derivative [Line Items]
Fair Value Inputs, Discount Rate			14.00%

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, at cost	$ 519,226	$ 448,921
Less: Accumulated depreciation	(298,051)	(236,542)
Property, plant and equipment, net	$ 221,175	$ 212,379

Goodwill and Intangibles (Detai

Goodwill and Intangibles (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Finite And Indefinite Lived Intangible Assets [Line Items]
Goodwill, Purchase Accounting Adjustments	$ (917)
Transfer of IPRD to Intangible Asset	1,000
Goodwill [Roll Forward]
Goodwill at December 31, 2017	933,662
Foreign currency translation	(11,369)
Goodwill at September 30, 2018	921,376
Total intangibles	305,822	$ 310,829
Less: Accumulated amortization	96,232	79,828
Intangible assets, net	209,590	231,001
Future amortization [Abstract]
2,017	24,600
2,018	22,800
2,019	22,100
2,020	21,900
2,021	21,900
Indefinite-Lived Intangible Assets [Member] | Completed technology [Member]
Goodwill [Roll Forward]
Indefinite life intangibles	5,178	6,422
Finite-Lived Intangible Assets [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	300,644	304,407
Less: Accumulated amortization	96,232	79,828
Finite-Lived Intangible Assets [Member] | Distribution channels [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	900	900
Less: Accumulated amortization	835	640
Finite-Lived Intangible Assets [Member] | Completed technology [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	147,619	149,645
Less: Accumulated amortization	50,901	40,810
Finite-Lived Intangible Assets [Member] | Licenses [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	6,547	5,268
Less: Accumulated amortization	1,706	1,530
Finite-Lived Intangible Assets [Member] | Customer Relationships [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	127,807	129,693
Less: Accumulated amortization	28,414	23,268
Finite-Lived Intangible Assets [Member] | Trademarks [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	14,135	14,368
Less: Accumulated amortization	11,536	10,487
Finite-Lived Intangible Assets [Member] | Noncompete Agreements [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	3,111	3,964
Less: Accumulated amortization	2,315	2,603
Finite-Lived Intangible Assets [Member] | Other [Member]
Goodwill [Roll Forward]
Definite life intangibles, Cost	525	569
Less: Accumulated amortization	525	$ 490
UNITED STATES | Lower Extremities & Biologics [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Goodwill, Purchase Accounting Adjustments	0
Goodwill [Roll Forward]
Goodwill at December 31, 2017	218,525
Foreign currency translation	0
Goodwill at September 30, 2018	218,525
UNITED STATES | Upper Extremities [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Goodwill, Purchase Accounting Adjustments	(917)
Goodwill [Roll Forward]
Goodwill at December 31, 2017	630,650
Foreign currency translation	(1,111)
Goodwill at September 30, 2018	628,622
International [Member] | Extremities & Biologics [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Goodwill, Purchase Accounting Adjustments	0
Goodwill [Roll Forward]
Goodwill at December 31, 2017	84,487
Foreign currency translation	(10,258)
Goodwill at September 30, 2018	$ 74,229

Long-Term Debt and Capital Le_3

Long-Term Debt and Capital Lease Obligations (Details) $ / shares in Units, shares in Millions		Jul. 30, 2018USD ($)	Jun. 28, 2018USD ($)counterparty$ / sharesshares	Aug. 15, 2017USD ($)	Dec. 23, 2016	May 20, 2016USD ($)counterparty$ / sharesshares	May 12, 2016$ / shares	Nov. 24, 2015$ / shares	Feb. 13, 2015USD ($)counterparty$ / sharesshares	Aug. 31, 2012USD ($)$ / shares	Aug. 31, 2008	May 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 01, 2018shares	Sep. 24, 2017USD ($)	Mar. 31, 2015USD ($)	Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)shares	Dec. 31, 2017USD ($)	Sep. 25, 2016	Oct. 01, 2015$ / shares	Feb. 09, 2015$ / shares	Sep. 30, 2012USD ($)	Dec. 31, 2008USD ($)	Jul. 29, 2008
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations													$ 1,101,512,000				$ 1,101,512,000		$ 895,114,000
Less: current portion	[1],[2]												(514,930,000)				(514,930,000)		(58,906,000)
Long-term debt and capital lease obligations	[1]												586,582,000				586,582,000		836,208,000
Write off of pro-rata unamortized deferred financing fees and for bank and legal fees																	$ 39,935,000	$ 0
ThresholdForConversionAsPercentOfConversionPrice									130.00%		130.00%						130.00%
Threshold For Conversion									98.00%		98.00%						98.00%
Debt Instrument, Convertible, Minimum Consecutive Period										5 days	20 days						5 days
Debt Instrument, Convertible, Trading Period									30 days		30 days						30 days
Debt instrument, convertible, purchase price as a percent of principal amount if fundamental change event occurs									100.00%								100.00%
Amortization of Debt Discount (Premium)													5,000,000		$ 4,600,000		$ 14,800,000	13,400,000
Payments for Repurchase of Warrants																	23,972,000
Payment of notes hedge option																	34,553,000
Issuance of warrants																	102,137,000	0
Debt Issuance Costs, Line of Credit Arrangements, Gross													1,800,000				1,800,000		2,200,000
Debt Instrument, Description of Variable Rate Basis					0.0075							0.01
Fair Value Assumption, Date of Securitization or Asset-backed Financing Arrangement, Transferor's Continuing Involvement, Servicing Assets or Liabilities, Prepayment Speed												100.00%
Proceeds from Collaborators												$ 10,000,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage					1.00%
Line of Credit Facility, Minimum Borrowing Capacity as Percentage of Available Borrowing Capacity					20.00%
Line of Credit, Prepayment Penalty												1.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages													500,000				500,000		1,000,000
Term Loan [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Debt													20,000,000				20,000,000
Debt Issuance Costs, Net												$ 1,000,000
Capital Lease Obligations [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations													22,875,000				22,875,000		20,401,000
2023 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations													542,575,000				542,575,000		0
Stated percentage rate			1.625%
Debt instrument, convertible, conversion ratio			29.9679
Conversion price (in dollars per share) | $ / shares			$ 33.37
Debt Instrument, Convertible, Trading Period			120 days
Debt Instrument, Interest Rate, Effective Percentage			6.06%
Long-term Debt, Fair Value													715,800,000				715,800,000
Number of Counterparties | counterparty			2
Debt Instrument, Unamortized Discount													(119,519,000)				(119,519,000)
Unamortized Debt Issuance Expense													(12,906,000)				(12,906,000)
Incremental Common Shares Attributable to Call Options and Warrants | shares			20.2
Issuance of warrants			$ 102,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 40.86
Debt Issuance Costs, Net			$ 12,400,000
Debt Conversion, Converted Instrument, Amount Delivered			1,138.70
2023 Note Hedges [Member]
Debt and Capital Lease Obligations [Abstract]
Indebtedness in Excess, Default			25,000,000
2021 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Debt, Gross													395,000,000				395,000,000		395,000,000
Debt and Capital Lease Obligations	[2]												315,793,000				315,793,000		300,051,000
Stated percentage rate						2.25%
Maturity date						Nov. 15, 2021
Debt instrument, convertible, conversion ratio						46.8165
Conversion price (in dollars per share) | $ / shares						$ 21.36
Debt Instrument, Convertible, Trading Period							100 days
Debt Instrument, Interest Rate, Effective Percentage						9.72%
Long-term Debt, Fair Value													572,800,000				572,800,000
Number of Counterparties | counterparty						2
Debt Instrument, Unamortized Discount													(74,552,000)				(74,552,000)		(89,332,000)
Unamortized Debt Issuance Expense						$ (7,300,000)							(4,655,000)				(4,655,000)		(5,617,000)
Incremental Common Shares Attributable to Call Options and Warrants | shares						18.5
Issuance of warrants						$ 54,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 30
Strike Price, In Excess of Stock Price							69.00%
2020 convertibledebt [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations	[2]												170,798,000				170,798,000		513,014,000
Stated percentage rate									2.00%
Maturity date									Feb. 15, 2020
Write off of pro-rata unamortized deferred financing fees and for bank and legal fees			39,900,000			9,300,000
Debt instrument, convertible, conversion ratio								33.3949	32.3939
Conversion price (in dollars per share) | $ / shares								$ 29.94	$ 30.87
Amortization of Debt Discount (Premium)													$ 2,400,000		6,900,000		$ 16,700,000	$ 20,300,000
Debt Instrument, Interest Rate, Effective Percentage													8.54%				8.54%
Extinguishment of Debt, Amount						45,000,000
Long-term Debt, Fair Value													$ 204,700,000				$ 204,700,000
Repayments of Debt						44,600,000			$ 292,000,000
Payments for Repurchase of Warrants						3,300,000
Payment of notes hedge option						600,000
Proceeds from Warrant Exercises		$ 10,600,000
Debt Instrument, Unamortized Discount													(14,081,000)				(14,081,000)		(66,418,000)
Unamortized Debt Issuance Expense									$ (18,100,000)				(1,710,000)				(1,710,000)		(8,068,000)
Incremental Common Shares Attributable to Call Options and Warrants | shares									20.5					6.2				19.6
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																					$ 38.8010	$ 40
Warrant Strike Price in Excess of Common Stock Price, Percent																						59.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									21.1
Debt Conversion, Converted Instrument, Amount			$ 400,900,000
2017 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations													18,903,000				$ 18,903,000		0
Stated percentage rate										2.00%
Maturity date																	Aug. 15, 2017
Debt instrument, convertible, conversion ratio											39.3140
Conversion price (in dollars per share) | $ / shares										$ 25.44
Extinguishment of Debt, Amount						54,400,000
Repayments of Debt				$ 2,000,000		56,300,000			$ 240,000,000
Payments for Repurchase of Warrants									60,000,000
Payment of notes hedge option									10,000,000
Unamortized Debt Issuance Expense																							$ (8,800,000)
Line of Credit [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations													21,549,000				$ 21,549,000		53,600,000
Line of Credit Facility, Maximum Borrowing Capacity																			150,000,000
Shareholder Debt- TRNX [Member]
Debt and Capital Lease Obligations [Abstract]
Notes Payable, Noncurrent													1,500,000				1,500,000		1,600,000
Other Debt Obligations [Member]
Debt and Capital Lease Obligations [Abstract]
Debt and Capital Lease Obligations													$ 9,019,000				$ 9,019,000		8,003,000
Minimum [Member]
Debt and Capital Lease Obligations [Abstract]
Debt Instrument, Interest Rate, Effective Percentage													2.55%				2.55%
Maximum [Member]
Debt and Capital Lease Obligations [Abstract]
Debt Instrument, Interest Rate, Effective Percentage													4.90%				4.90%
Maximum [Member] | Line of Credit [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity																			100,000,000
2020 Conversion Derivative [Member]
Debt and Capital Lease Obligations [Abstract]
Debt Instrument, Unamortized Discount									$ (149,800,000)
2017 Notes Conversion Derivative [Member]
Debt and Capital Lease Obligations [Abstract]
Write off of pro-rata unamortized deferred financing fees and for bank and legal fees															$ 3,000,000	$ 25,100,000
Debt Instrument, Interest Rate, Effective Percentage																				6.47%
Debt Instrument, Unamortized Discount										$ (48,100,000)
Mr. Tornier [Member]
Debt and Capital Lease Obligations [Abstract]
Equity Method Investment, Ownership Percentage																									49.00%
Other Borrowings																								$ 2,200,000
Tornier SAS [Member]
Debt and Capital Lease Obligations [Abstract]
Equity Method Investment, Ownership Percentage																									51.00%
Base Rate [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit Facility, Interest Rate at Period End					3.00%
Variable Income Interest Rate [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit Facility, Interest Rate at Period End					4.00%							8.00%
Secured Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Line of Credit													$ 21,549,000				$ 21,549,000		53,645,000
Euro London Interbank Offered Rate (Euro LIBROR) [Member] | Shareholder Debt- TRNX [Member]
Debt and Capital Lease Obligations [Abstract]
Debt Instrument, Basis Spread on Variable Rate																	0.00%
Term Loan [Member] | Line of Credit [Member] | Secured Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity												$ 40,000,000
Debt Instrument, Term												2 years
Other Debt [Member] | Notes Payable, Other Payables [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Debt													6,000,000				$ 6,000,000		4,200,000
2020 Notes Hedges [Member]
Debt and Capital Lease Obligations [Abstract]
Number of Counterparties | counterparty									3
Indebtedness in Excess, Default									$ 25,000,000
Derivative, Cost of Hedge									144,800,000
IMASCAP SAS [Member]
Debt and Capital Lease Obligations [Abstract]
Loans Payable													1,000,000				1,000,000		1,200,000
Debt Instrument, Tranche 1 [Member] | Term Loan [Member] | Line of Credit [Member] | Secured Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity												$ 20,000,000
Debt Instrument, Tranche 2 [Member] | Term Loan [Member] | Line of Credit [Member] | Secured Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity												$ 20,000,000
Reported Value Measurement [Member] | 2021 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Debt, Gross						$ 395,000,000
Reported Value Measurement [Member] | 2020 convertibledebt [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Debt, Gross									$ 632,500,000				$ 186,589,000				$ 186,589,000		$ 587,500,000
Reported Value Measurement [Member] | 2017 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Long-term Debt, Gross										$ 300,000,000
Debt Instrument, Tranche 1 [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit, Prepayment Penalty					3.00%
Debt Instrument, Tranche 2 [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit, Prepayment Penalty					2.00%
Debt Instrument, Tranche 3 [Member]
Debt and Capital Lease Obligations [Abstract]
Line of Credit, Prepayment Penalty					0.75%
2023 Note Hedges [Member]
Debt and Capital Lease Obligations [Abstract]
Number of Counterparties | counterparty			2
Derivative, Cost of Hedge			$ 141,300,000
2021 Notes Hedges [Member]
Debt and Capital Lease Obligations [Abstract]
Number of Counterparties | counterparty						2
2020 convertibledebt [Member] | 2021 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Extinguishment Of Debt, Amount Delivered Per Incremental Amount Exchanged						$ 990
2017 Convertible Debt [Member] | 2021 Convertible Debt [Member]
Debt and Capital Lease Obligations [Abstract]
Extinguishment Of Debt, Amount Delivered Per Incremental Amount Exchanged						$ 1,035.40
Circumstance 1 [Domain]
Debt and Capital Lease Obligations [Abstract]
Debt Instrument, Convertible, Minimum Consecutive Period																	20 days
[1]	1 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes and the fair value of the 2021 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2021 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. Additionally, the holders of the 2020 Notes will have the ability to begin converting their 2020 Notes beginning August 15, 2019 through their maturity. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes and the fair value of the 2020 Notes Conversion Derivative were classified as current liabilities, and the fair value of the 2020 Notes Hedges were classified as current assets as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017. See Note 6 and Note 9.
[2]	1 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes were classified as current liabilities as of September 30, 2018. The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash upon satisfaction of certain circumstances as described below. On or after August 15, 2019, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes were classified as current liabilities as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017.

Long-Term Debt and Capital Le_4

Long-Term Debt and Capital Lease Obligations - 2023 Notes (Details) $ / shares in Units, $ in Thousands, shares in Millions		Jun. 28, 2018USD ($)counterparty$ / sharesshares	May 20, 2016USD ($)counterparty$ / sharesshares	May 12, 2016$ / shares	Feb. 13, 2015	Aug. 31, 2012	Aug. 31, 2008	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Debt Instrument, Convertible, Minimum Consecutive Period						5 days	20 days		5 days
Debt Instrument, Convertible, Trading Period					30 days		30 days		30 days
ThresholdForConversionAsPercentOfConversionPrice					130.00%		130.00%		130.00%
Threshold For Conversion					98.00%		98.00%		98.00%
Debt instrument, convertible, purchase price as a percent of principal amount if fundamental change event occurs					100.00%				100.00%
Debt and Capital Lease Obligations								$ 1,101,512	$ 1,101,512		$ 895,114
Issuance of warrants									102,137	$ 0
2021 Convertible Debt [Member]
Debt Instrument [Line Items]
Stated percentage rate			2.25%
Debt instrument, convertible, conversion ratio			46.8165
Conversion price (in dollars per share) | $ / shares			$ 21.36
Debt Instrument, Convertible, Trading Period				100 days
Debt Instrument, Unamortized Discount								(74,552)	(74,552)		(89,332)
Unamortized Debt Issuance Expense			$ (7,300)					(4,655)	(4,655)		(5,617)
Debt and Capital Lease Obligations	[1]							315,793	315,793		300,051
Long-term Debt, Fair Value								572,800	572,800
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | shares			18.5
Number of Counterparties | counterparty			2
Issuance of warrants			$ 54,600
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 30
2021 Notes Hedges [Member]
Debt Instrument [Line Items]
Indebtedness in Excess, Default			$ 25,000
2023 Note Hedges [Member]
Debt Instrument [Line Items]
Indebtedness in Excess, Default		$ 25,000
2023 Convertible Debt [Member]
Debt Instrument [Line Items]
Principal Amount		$ 675,000						675,000	675,000
Stated percentage rate		1.625%
Debt instrument, convertible, conversion ratio		29.9679
Conversion price (in dollars per share) | $ / shares		$ 33.37
Debt Instrument, Convertible, Trading Period		120 days
Debt Issuance Costs, Net		$ 12,400
Derivative Liability		$ 124,600
Interest Expense, Debt								4,900	5,100
Debt Instrument, Unamortized Discount								(119,519)	(119,519)
Unamortized Debt Issuance Expense								(12,906)	(12,906)
Debt and Capital Lease Obligations								542,575	542,575		$ 0
Long-term Debt, Fair Value								$ 715,800	$ 715,800
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | shares		20.2
Number of Counterparties | counterparty		2
Issuance of warrants		$ 102,100
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 40.86
2021 Notes Hedges [Member]
Debt Instrument [Line Items]
Number of Counterparties | counterparty			2
Circumstance 1 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Minimum Consecutive Period									20 days
[1]	1 As of September 30, 2018, the closing price of our ordinary shares was greater than 130% of the 2021 Notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end; and, therefore, the holders of the 2021 Notes may convert the notes during the succeeding quarterly period. Due to the ability of the holders of the 2021 Notes to convert the notes during this period, the carrying value of the 2021 Notes were classified as current liabilities as of September 30, 2018. The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash upon satisfaction of certain circumstances as described below. On or after August 15, 2019, holders may convert their 2020 Notes solely into cash, regardless of the foregoing circumstances. Due to the ability of the holders of the 2020 Notes to convert within the next year, the carrying value of the 2020 Notes were classified as current liabilities as of September 30, 2018. The respective balances were classified as long-term as of December 31, 2017.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017	Dec. 31, 2017	Dec. 25, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity Attributable to Parent	$ 958,498	$ 538,516	$ 958,498	$ 538,516	$ 588,696	$ 686,864
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax			(19,642)	44,362
Accumulated Other Comprehensive Income (Loss), Net of Tax	2,648		2,648		22,290
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity Attributable to Parent	2,648	24,901	2,648	24,901	$ 22,290	$ (19,461)
Accumulated Other Comprehensive Income (Loss) [Member] | Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(2,773)	25,132	(19,642)	44,362
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ 2,648	$ 24,901	$ 2,648	$ 24,901

Changes in Stockholders' Equi_3

Changes in Stockholders' Equity (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017
Stockholders' Equity Attributable to Parent, Beginning Balance			$ 588,696	$ 686,864
Net (loss) income	$ (42,525)	$ (131,870)	(135,737)	(231,731)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax			(19,642)	44,362
Stock Issued During Period, Value, New Issues			10,975	24,828
Stock Issued During Period, Value, Other			423,012
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition			18,238	14,193
Stockholders' Equity Attributable to Parent, Ending Balance	$ 958,498	$ 538,516	958,498	$ 538,516
Adjustments to Additional Paid in Capital, Warrant Issued			$ 72,956
Common Stock [Member]
Common Stock, Shares, Outstanding, Beginning Balance			105,807	103,401
Stockholders' Equity Attributable to Parent, Beginning Balance			$ 3,896	$ 3,815
Stock Issued During Period, Shares, New Issues			557	1,217
Stock Issued During Period, Value, New Issues			$ 20	$ 40
Stock Issued During Period, Shares, Other			18,249
Stock Issued During Period, Value, Other			$ 641
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures			452	394
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			$ 16	$ 13
Common Stock, Shares, Outstanding, Ending Balance	125,065	105,012	125,065	105,012
Stockholders' Equity Attributable to Parent, Ending Balance	$ 4,573	$ 3,868	$ 4,573	$ 3,868
Additional Paid-in Capital [Member]
Stockholders' Equity Attributable to Parent, Beginning Balance			1,971,347	1,908,749
Stock Issued During Period, Value, New Issues			10,955	24,788
Stock Issued During Period, Value, Other			422,371
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			(16)	(13)
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition			18,238	14,193
Stockholders' Equity Attributable to Parent, Ending Balance	2,495,851	1,947,717	2,495,851	1,947,717
Adjustments to Additional Paid in Capital, Warrant Issued			72,956
Retained Earnings [Member]
Stockholders' Equity Attributable to Parent, Beginning Balance			(1,408,837)	(1,206,239)
Stockholders' Equity Attributable to Parent, Ending Balance	(1,544,574)	(1,437,970)	(1,544,574)	(1,437,970)
Accumulated Other Comprehensive Income (Loss) [Member]
Stockholders' Equity Attributable to Parent, Beginning Balance			22,290	(19,461)
Stockholders' Equity Attributable to Parent, Ending Balance	2,648	24,901	2,648	24,901
Accumulated Translation Adjustment [Member] | Accumulated Other Comprehensive Income (Loss) [Member]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ (2,773)	$ 25,132	$ (19,642)	$ 44,362

Capital Stock and Earnings per

Capital Stock and Earnings per share Capital Stock (Details) $ / shares in Units, $ in Thousands	Jun. 28, 2018shares	May 20, 2016shares	Feb. 13, 2015shares	Sep. 30, 2018USD ($)$ / sharesshares	Jul. 01, 2018shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 24, 2017shares	Sep. 30, 2018€ / sharesshares	Dec. 31, 2017€ / sharesshares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares Issued, Price Per Share | $ / shares				$ 24.60		$ 24.60
Stock Issued | $				$ 448,900
Proceeds from equity offering | $						$ 448,924
Payments of Stock Issuance Costs | $						$ 25,566
Common stock, shares authorized (in shares)				320,000,000		320,000,000		320,000,000	320,000,000
Common Stock, Par or Stated Value Per Share | € / shares								€ 0.03	€ 0.03
Common Stock, Shares, Issued				125,065,240		125,065,240		125,065,240	105,807,424
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount						10,400,000	10,400,000
Antidilutive Securities Stock Options						1,300,000	1,400,000
Antidilutive securities, non-vested shares, performance shares				200,000		200,000	100,000	200,000
2020convertibledebt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants			20,500,000		6,200,000		19,600,000
2021 Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants		18,500,000
2023 Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants	20,200,000
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock Issued During Period, Shares, Other						18,249,000
Sale of Stock [Domain]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Proceeds from equity offering | $						$ 423,011
Discount and Commissions [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Payments of Stock Issuance Costs | $						25,421
Other Offering Costs [Domain]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Payments of Stock Issuance Costs | $						$ 492

Earnings per share (Details)

Earnings per share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 24, 2017	Sep. 30, 2018	Sep. 24, 2017
Earnings Per Share [Abstract]
Weighted-average number of ordinary shares outstanding-basic and diluted (in shares)	113,043	104,836	108,348	104,292

Commitments and Contingencies -

Commitments and Contingencies - Product Liability Contingency (Details) - USD ($) $ in Thousands

May 08, 2018

May 01, 2018

Apr. 30, 2018

Apr. 19, 2018

Mar. 29, 2018

Feb. 22, 2018

Oct. 03, 2017

Sep. 01, 2015

Dec. 25, 2016

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2018

Dec. 31, 2017

Dec. 27, 2015

Jan. 02, 2018

Nov. 01, 2016

Product Liability Contingency [Line Items]

Restricted Cash and Cash Equivalents, Current

$ 150,000

Third Party Recovery

$ 10,000

$ 5,000

PROFEMUR Titanium Modular Neck Product [Member]

Product Liability Contingency [Line Items]

Insurance Settlements Receivable, Current

$ 0

Allowance for Doubtful Accounts Receivable, Write-offs

$ 25,000

Product liability, current

11,700

Product liability, non-current

6,500

Increase Decrease in Estimated Recovery from Third Party

$ 19,400

Loss Contingency, Receivable, Period Increase (Decrease)

$ 25,000

CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Loss Contingency Accrual

105,600

Master Settlement Agreement - MDL & JCCP [Member]

Product Liability Contingency [Line Items]

Percent Of Claimants Opted-In

99.00%

Master Settlement Agreement - MDL & JCCP [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Loss Contingency Accrual

240,000

Accrual for eligible claims in excess of 1292 excluded from MSA [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Loss Contingency Accrual

9,400

Second Settlement Agreement [Member]

Product Liability Contingency [Line Items]

Percent Of Claimants Opted-In

100.00%

Second Settlement Agreement [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Loss Contingency Accrual

82,700

Litigation Settlement, Amount Awarded to Other Party

$ 89,750

Metal-On-Metal Claims [Member]

Product Liability Contingency [Line Items]

Proceeds From Insurance Policies

$ 101,900

Proceeds From Insurance Policies, Paid Directly To Entity

95,200

Proceeds From Insurance Policies, Paid To Third Party Claimants

6,700

Minimum [Member] | PROFEMUR Titanium Modular Neck Product [Member]

Product Liability Contingency [Line Items]

Estimated product liability range

18,200

Accrued Liabilities, Current [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Loss Contingency Accrual

88,800

Other Noncurrent Liabilities [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Loss Contingency Accrual

16,800

Insurance Carrier [Member]

Product Liability Contingency [Line Items]

Proceeds from Legal Settlements

$ 30,750

Insurance Policy Limit

25,000

Insurance Policy, Costs And Interest Received

$ 5,750

Columbia [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Insurance Recoveries

$ 60,000

10,000

Federal [Member]

Product Liability Contingency [Line Items]

Proceeds from Legal Settlements

$ 15,000

5,000

Lloyd's Of London Syndicate 2003 [Member]

Product Liability Contingency [Line Items]

Proceeds from Legal Settlements

$ 2,000

$ 5,000

Lexington [Member] | Metal-On-Metal Claims [Member]

Product Liability Contingency [Line Items]

Policy Limits Remaining

30,000

Catlin [Member] | Metal-On-Metal Claims [Member]

Product Liability Contingency [Line Items]

Policy Limits Remaining

$ 5,000

Tranche 1 [Member] | Second Settlement Agreement [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Litigation Settlement, Amount Awarded to Other Party

7,900

Tranche 2 [Member] | Second Settlement Agreement [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Litigation Settlement, Amount Awarded to Other Party

5,100

Tranche 3 [Member] | Second Settlement Agreement [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Litigation Settlement, Amount Awarded to Other Party

76,750

Litigation Settlement, Amount, Net Of Insurance Deficit

45,000

Litigation Settlement, Amount, Insurance Deficit

$ 13,100

Tranche 3 [Member] | Third Settlement Agreement [Member] | CONSERVE (R) DYNASTY (R) AND LINEAGE (R) [Member]

Product Liability Contingency [Line Items]

Insurance Recoveries

$ 21,900

Loss Contingency, Estimated Recovery from Third Party

35

Settlement Costs

$ 5,000

Litigation Settlement, Amount Awarded to Other Party

$ 541,000

Litigation Settlement, Amount, Insurance Deficit

$ 13,100

Segment Data (Details)

Segment Data (Details) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 24, 2017USD ($)	Dec. 31, 2017USD ($)
Segment Reporting Information [Line Items]
Interest Income (Expense), Nonoperating, Net		$ (19,753)	$ (18,978)	$ (60,243)	$ (55,512)
Net sales		194,106	170,503	598,043	527,387
Operating Income (Loss)		(9,134)	(18,509)	(11,682)	(36,900)
Transaction and Transition Expense		1,952	3,311	4,187	9,484
Other Nonoperating Income (Expense)		3,902	5,457	75,649	6,875
Assets		2,839,295		2,839,295		$ 2,128,724
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest		(32,789)	(42,944)	(147,574)	(99,287)
EMEA [Member]
Segment Reporting Information [Line Items]
Net sales		32,931	29,496	113,122	97,732
UNITED STATES
Segment Reporting Information [Line Items]
Net sales		145,565	126,864	441,933	391,954
Other
Segment Reporting Information [Line Items]
Net sales		15,610	14,143	42,988	37,701
Extremities & Biologics [Member] | EMEA [Member]
Segment Reporting Information [Line Items]
Net sales		1,828	1,727	6,244	6,159
Extremities & Biologics [Member] | International [Member]
Segment Reporting Information [Line Items]
Net sales		48,541	43,639	156,110	135,433
Depreciation		3,366	3,298	9,604	8,539
AmortizationExpenseWithoutDistributorConversion		0	0	0	0
Segment Operating Loss		(278)	(1,563)	(1,526)	1,641
Assets		249,051		249,051		301,985
Extremities & Biologics [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Net sales		20,654	18,640	59,053	56,547
Extremities & Biologics [Member] | Other
Segment Reporting Information [Line Items]
Net sales		4,721	3,466	12,144	9,333
Lower Extremities & Biologics [Member] | EMEA [Member]
Segment Reporting Information [Line Items]
Net sales		9,527	9,022	33,761	30,379
Lower Extremities & Biologics [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Net sales		57,602	51,417	173,889	161,228
Lower Extremities & Biologics [Member] | Other
Segment Reporting Information [Line Items]
Net sales		3,974	4,941	10,747	11,993
Upper Extremities [Member] | EMEA [Member]
Segment Reporting Information [Line Items]
Net sales		18,985	15,779	64,935	51,193
Upper Extremities [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Net sales		65,334	54,788	203,163	168,280
Upper Extremities [Member] | Other
Segment Reporting Information [Line Items]
Net sales		6,696	5,418	19,477	15,413
Sports Med And Other [Member] | EMEA [Member]
Segment Reporting Information [Line Items]
Net sales		2,591	2,968	8,182	10,001
Sports Med And Other [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Net sales		1,975	2,019	5,828	5,899
Sports Med And Other [Member] | Other
Segment Reporting Information [Line Items]
Net sales		219	318	620	962
UNITED STATES | Lower Extremities & Biologics [Member]
Segment Reporting Information [Line Items]
Net sales		79,296	70,946	235,595	220,259
Depreciation		2,474	3,871	7,729	10,080
AmortizationExpenseWithoutDistributorConversion		0	0	0	0
Segment Operating Loss		20,487	13,506	62,211	51,988
Assets		524,265		524,265		490,528
UNITED STATES | Upper Extremities [Member]
Segment Reporting Information [Line Items]
Net sales		66,269	55,918	206,338	171,695
Depreciation		2,836	2,372	8,350	7,321
AmortizationExpenseWithoutDistributorConversion		0	0	0	0
Segment Operating Loss		21,192	16,575	69,864	52,942
Assets		922,120		922,120		929,930
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Net sales	[1]	0	0	0	0
Depreciation	[1]	5,928	5,459	17,303	16,184
AmortizationExpenseWithoutDistributorConversion	[1]	5,881	7,178	19,031	21,574
Segment Operating Loss	[1]	(48,583)	(43,716)	(138,044)	(133,987)
Assets		1,143,859		$ 1,143,859		$ 406,281
segment [Member]
Segment Reporting Information [Line Items]
Number of Reportable Segments				3
Depreciation		14,604	15,000	$ 42,986	42,124
AmortizationExpenseWithoutDistributorConversion		5,881	7,178	19,031	21,574
Segment Operating Loss		$ (7,182)	$ (15,198)	$ (7,495)	$ (27,416)
[1]	1 The Corporate category primarily reflects general and administrative expenses not specifically associated with the U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics segments. These non-allocated corporate expenses relate to global administrative expenses that support all segments, including salaries and benefits of certain executive officers and expenses such as: information technology administration and support; corporate headquarters; legal, compliance, and corporate finance functions; insurance; and all share-based compensation

Subsequent Event Subsequent E_2

Subsequent Event Subsequent Event (Details) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2018	Oct. 10, 2018
Subsequent Event [Line Items]
Proceeds from equity offering	$ 448,924
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Other	18,249
Cartiva, Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Business Acquisition, Transaction Costs		$ 435,000

Uncategorized Items - wmgi-2018

Label	Element	Value
Restricted Cash	us-gaap_RestrictedCash	$ 150,000,000
Cash	us-gaap_Cash	$ 262,300,000